Research Progress of Multicomponent Co-Loaded Nanomedicine Delivery Systems for Tumor Immunotherapy Authors: Tianying Sun, Chuanguo Liu, Jiang Zhu, Kai Gong, Mengzhen Xu, Qingjun Zhu, Hong Guo Published: 2026 ABSTRACT AbstractTumor immunotherapy has substantially advanced cancer treatment by activating or enhancing the antitumor immune response. However, tumor heterogeneity, the immunosuppressive tumor microenvironment (TME), and therapeutic resistance limit the efficacy of single-agent immunotherapy, making mechanistically complementary multicomponent combination strategies a rational approach to improve therapeutic outcomes. Conventional drug combinations are often constrained by differences in their physicochemical properties and pharmacokinetics, which hinder precise control of predefined synergistic ratios at the target site. Multicomponent co-loaded nanomedicine delivery systems have emerged as a promising platform capable of co-delivering therapeutics with distinct mechanisms of action to the TME at defined ratios. Such systems can integrate established immunotherapeutic agents with conventional therapeutic agents that exert experimentally supported immunomodulatory effects and, through spatiotemporally coordinated delivery and release, achieve complementary tumor control and immune activation by enhancing antigen presentation, reversing immunosuppression, or inducing immunogenic cell death. This review systematically summarizes recent advances in multicomponent co-loaded nanomedicine systems for tumor immunotherapy, with a focus on design principles, component selection, ratio optimization, release kinetics, and immunomodulatory mechanisms. We further discuss key challenges, including formulation compatibility, reproducibility, safety, scalable manufacturing, and clinical translation, with the aim of providing a rational framework and practical guidance for the development of effective and safe nanomedicine-based combination immunotherapies.Keywords: tumor immunotherapy, multicomponent co-loading, combination immunotherapy, tumor microenvironment, drug delivery Introduction Malignant tumors are the second leading cause of death worldwide.1 In recent years, emerging technologies have substantially deepened our understanding of cancer biology: multi-omics approaches have systematically uncovered the mechanisms underlying tumor pathogenesis and therapeutic resistance, while artificial intelligence (AI)-powered systems have driven notable progress in early cancer detection and personalized clinical management, laying an important foundation for precision oncology.2,3 Nevertheless, these advances in mechanistic cognition and diagnostic capabilities have not fundamentally resolved the inherent shortcomings of conventional cancer treatments. Existing clinical treatment modalities, such as surgery, chemotherapy, and radiotherapy, may be associated with multiple limitations, including high recurrence rates, severe side effects, and irreversible damage to normal tissues.4 Increasing attention has been directed toward leveraging the immune system to target tumors, driven by advances in the understanding of the tumor microenvironment (TME). Tumor immunotherapy is defined as a therapeutic strategy that directly modulates the host immune system to suppress and eradicate tumor cells, covering core modalities such as immune checkpoint inhibitors, adoptive cell therapy and cancer vaccines.5 It is distinguished from conventional therapies that only exert secondary immunomodulatory effects. Immunotherapy has several benefits over traditional cancer treatments, including reduced invasiveness and superior specificity.6 Moreover, tumor immunotherapy may help reduce the risk of metastasis and recurrence by eliminating circulating tumor cells and establishing long-term immune memory. Tumor immunotherapy has made significant strides in recent years.7,8 The primary existing tumor immunotherapy strategies include immune checkpoint blockade (ICB), macrophage polarization regulation (MPR), adoptive immune cell therapy (ACT), and cancer vaccine therapeutics etc (Table 1).9 However, restricted by tumor heterogeneity, an immunosuppressive tumor microenvironment, primary and acquired therapeutic resistance, and low objective response rates in “immune-cold” tumors, triggering anti-tumor immunity through a single target frequently fails to achieve satisfactory and durable therapeutic effects.10,11 To overcome these limitations, mechanistically complementary combination therapies have been developed to enhance treatment efficacy through the simultaneous targeting of multiple pathways. Mechanistically, these strategies may combine immune checkpoint blockade with chemotherapy-induced immunogenic cell death, cytokine-mediated immune activation, nucleic acid-based regulation, cancer vaccination, or TME remodeling to enhance antigen release and presentation, relieve immunosuppression, and activate effector immune cells.12,13 In terms of delivery format, therapeutic agents may be administered sequentially using separate carriers or co-loaded within a single nanocarrier through ratio-controlled, hierarchical, or stimuli-responsive designs.14 Table 1Characteristics of Tumor Immunotherapy StrategiesTypeArchetypal RepresentativeAdvantagesDisadvantagesScope of ApplicationICBPD-1/PD-L1 inhibitors (pembrolizumab, nivolumab, etc)CTLA-4 inhibitors (ipilimumab, etc), etcCompared to chemotherapy, it has a generally relatively low toxicity profile.1. The effectiveness of immune checkpoint blockade therapy is impacted by low response rates and individual variability.152. Only 20–30% of cancer patients benefit from CTLA-4 or PD-1 blockade.163. There was a notable variation in the frequency of major adverse events (58% vs 21%).171. Cancer types with high mutation rates that are easily recognized by the immune system (melanoma, non-small cell lung cancer, etc).172. Tumor subtypes characterized by mismatch repair gene defects (microsatellite-unstable colorectal cancer, etc).17,183. Combination therapy, such as for hepatocellular carcinoma,19 renal cell carcinoma,20 gastric cancer,21 etcMPRToll-like receptor agonists (LPS, CpG oligonucleotides, etc)PPARγagonists (rosiglitazone, pioglitazone, etc)STAT signaling modulators (interferon-γ, etc)PI3K/Akt/mTOR pathway modulators (rapamycin, etc), etcThe combination of chemotherapy and ICB can improve therapeutic efficacy, and there is a considerable chance of synergistic effects through multiple mechanisms.221. Macrophages exhibit high plasticity, making it difficult to sustain the M1 state long-term.232. Off-target hazards are comparatively substantial and can cause tissue injury or systemic inflammation.24Suitable for “cold tumors” with low T cell infiltration and strong immunosuppression (pancreatic ductal adenocarcinoma,25 glioblastoma,26 breast cancer,27,28 etc)ACTTIL therapy, CAR/TCR-T therapyCAR-M therapyCAR-NK therapy, etcIt is possible to apply customized treatment based on the patient’s unique antigens (TILs, etc).291. Limited efficacy in solid tumors; TME suppress cell activity and impede penetration.302. Serious side effects.3. Complex to prepare and costly.Leukemia, lymphoma, and other blood cancers.31–33Cancer vaccine therapeuticsHPV vaccine, Provenge (Sipuleucel-T, etc)CIMAvax-EGF, etc1. High safety profile with minimal side effects.2. Provides long-term protection with immune memory to prevent recurrence.341. The scope of application is relatively narrow, being effective only for cancers associated with specific pathogens.352. The therapeutic effect is limited, but it is more effective when used in combination with other therapies.1. Cancers with distinct shared antigens, such as prostate cancer36 and HPV-associated cancers (cervical cancer,37 etc).2. Cancers with high mutation burdens (melanoma,38 non-small cell lung cancer,39 etc)Cytokine therapyInterferon (IFN)Interleukins (IL)Tumor necrosis factor (TNF)Colony-stimulating factor (CSF), etc1. Activate immune cells directly.402. Combining ICB with chemotherapy can enhance treatment efficacy.1. Short half-life, requiring frequent dosing; poor patient tolerance.412. Monotherapy is generally ineffective against most solid tumors.421. Cancer types suitable for high-dose monotherapy: metastatic melanoma, metastatic renal cell carcinoma,41,43 etc2. Combination therapy for conditions such as melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, and bladder cancer,41 etcAbbreviations: ACT, adoptive immune cell therapy; Akt, protein kinase B; CAR, chimeric antigen receptor; CAR-M, chimeric antigen receptor macrophage; CAR-NK, chimeric antigen receptor natural killer cell; CAR-T, chimeric antigen receptor T cell; CpG, CpG oligonucleotide; CSF, colony-stimulating factor; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; EGF, epidermal growth factor; HPV, human papillomavirus; ICB, immune checkpoint blockade; IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; MPR, macrophage polarization regulation; mTOR, mechanistic target of rapamycin; NK, natural killer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PI3K, phosphoinositide 3-kinase; PPARγ, peroxisome proliferator-activated receptor gamma; STAT, signal transducer and activator of transcription; TCR, T-cell receptor; TIL, tumor-infiltrating lymphocyte; TME, tumor microenvironment; TNF, tumor necrosis factor. Characteristics of Tumor Immunotherapy Strategies Abbreviations: ACT, adoptive immune cell therapy; Akt, protein kinase B; CAR, chimeric antigen receptor; CAR-M, chimeric antigen receptor macrophage; CAR-NK, chimeric antigen receptor natural killer cell; CAR-T, chimeric antigen receptor T cell; CpG, CpG oligonucleotide; CSF, colony-stimulating factor; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; EGF, epidermal growth factor; HPV, human papillomavirus; ICB, immune checkpoint blockade; IFN, interferon; IL, interleukin; LPS, lipopolysaccharide; MPR, macrophage polarization regulation; mTOR, mechanistic target of rapamycin; NK, natural killer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PI3K, phosphoinositide 3-kinase; PPARγ, peroxisome proliferator-activated receptor gamma; STAT, signal transducer and activator of transcription; TCR, T-cell receptor; TIL, tumor-infiltrating lymphocyte; TME, tumor microenvironment; TNF, tumor necrosis factor. Combination therapy with traditional drugs can improve the efficacy of tumor immunotherapy to some extent, but this method still has limitations (Figure 1). On the one hand, only a limited proportion of traditional therapeutic agents can effectively reach the TME during in vivo delivery. To enhance therapeutic efficacy, increasing the dosage is often necessary, which imposes a substantial systemic burden.44,45 On the other hand, the synergistic effects of combination therapy are highly dependent on synchronized drug exposure and optimal concentration ratios of the multicomponent drugs within the tumor tissues.46 However, heterogeneity in the physicochemical properties and pharmacokinetic profiles of different agents makes it difficult for conventional administration strategies to precisely maintain predetermined drug concentration ratios at tumor sites, thereby limiting the efficacy of combination therapy.47 Therefore, based on comprehensive analyses of physicochemical differences, pharmacokinetic characteristics, and antitumor mechanisms, the development of strategies capable of efficiently co-delivering multiple agents to tumor sites at predefined ratios represents a critical approach for overcoming the bottleneck of nonuniform drug distribution in combination therapy. Limitations of traditional combination therapies and advantages of nanomedicine systems. Nanomedicine systems are widely regarded as an effective strategy for enhancing tumor immunotherapy because of their inherent advantages, including superior targeting capabilities and stimuli-responsive drug release.48 Initially, nanomedicine delivery systems were primarily designed for the delivery of single therapeutic agents. With the widespread adoption of combination therapies and the rapid advances of modern nanomedicine, multicomponent co-loaded nanomedicine delivery systems (hereafter referred to as “multicomponent nanomedicine systems” or simply “nanomedicine systems”) have emerged. Notably, high-quality multicomponent nanomedicine systems are not limited to simple physical co-loading of multiple agents; they can achieve synchronized pharmacokinetics, coordinated tumor distribution and programmed release matching the immune response sequence, thus supporting mechanistically synchronized anti-tumor immune responses.49 These systems may not only help address challenges associated with traditional combination drug delivery, such as difficulties in precisely controlling drug ratios and poor delivery stability, but may also enhance antitumor immune responses and increase tumor sensitivity to immunotherapy.50 To provide theoretical foundations and technical insights for the development of more effective and safer novel tumor immunotherapeutic strategies, this review aims to comprehensively analyze the design principles and recent research advances of multicomponent nanomedicine systems for tumor immunotherapy. Currently, multicomponent nanomedicine systems for tumor immunotherapy are undergoing rapid development. The number and types of therapeutic components directly influence the construction strategies, loading efficiency, and release kinetics of nanomedicine systems. Therefore, this review categorizes nanomedicine systems according to the number and types of therapeutic agents they co-load, classifying them into dual-component and triple-component nanomedicine systems. It systematically analyzes the key challenges and corresponding solutions associated with nanomedicine systems designed for the co-delivery of different therapeutic agents, and further summarizes the evaluation criteria for successful multicomponent nanomedicines and their application prospects (Figure 2). A list of abbreviations used throughout this review is provided in Table 6. Schematic diagram of multicomponent co-loaded nanomedicine delivery systems for tumor immunotherapy. Table 6List of AbbreviationsAcronymFull Form1-MTDextro-1-methyl tryptophanACTAdoptive immune cell therapyAIArtificial intelligenceAktProtein kinase BAMLAcute myeloid leukemiaAPAngelica sinensis polysaccharideAPIAminopropylimidazoleAsAstragaloside IVATEZOAtezolizumabATPAdenosine triphosphateBAPE4-hydroxybenzeneboronic acid pinacol esterBBBBlood–brain barrierBERBerberinebFGFBasic fibroblast growth factorCAFsCancer-associated fibroblastsCARChimeric antigen receptorCDDPCisplatinCe6Chlorin e6cGAMP2′3′-cyclic GMP–AMPcGASCyclic GMP–AMP synthaseCMCSCarboxymethyl chitosanCOX-2Cyclooxygenase-2CpGCpG oligonucleotideCPT-11IrinotecanCQ5-carboxy-8-hydroxyquinolineCRTCalreticulinCSFColony-stimulating factorCTLCytotoxic T lymphocyteCTLA-4Cytotoxic T-lymphocyte-associated antigen 4CURCurcuminDAMPsDamage-associated molecular patternsDCsDendritic cellsDECDecitabineDHADihydroartemisininDHTDihydrotanshinone IDNADeoxyribonucleic acidDOXDoxorubicindsDNADouble-stranded DNADTXDocetaxelEGFEpidermal growth factorEPREnhanced permeability and retention effectFAFolateFDAFood and Drug AdministrationGAGambogic acidGCGemcitabine monophosphate/prodrugGEMGemcitabineGM-CSFGranulocyte-macrophage colony-stimulating factorHAHyaluronic acidHAPHydroxyapatiteHCCHepatocellular carcinomaHIF-1αHypoxia-inducible factor-1αHMGB1High mobility group box 1HPVHuman papillomavirusHSAHuman serum albuminI3AIngenol-3-angelateIAHAAminopropylimidazole- and alendronate-modified hyaluronic acidICBImmune checkpoint blockadeICDImmunogenic cell deathICGIndocyanine greenIDOIndoleamine 2,3-dioxygenaseIFNInterferonIFN-βInterferon-βIFN-γInterferon-γIgGImmunoglobulin GILInterleukinIL-1βInterleukin-1βIL-2Interleukin-2IL-4Interleukin-4IL-6Interleukin-6IL-10Interleukin-10IL-12Interleukin-12IRF3Interferon regulatory factor 3La3+Lanthanum ionsLaPLanthanum phosphateLDHLactate dehydrogenaseLMWHLow-molecular-weight heparinL-OHPOxaliplatinLPSLipopolysaccharidemAbMonoclonal antibodyM1-TAMsM1 tumor-associated macrophagesM2-TAMsM2 tumor-associated macrophagesMDRMultidrug resistanceMDSCsMyeloid-derived suppressor cellsMETMetforminMMP-2Matrix metalloproteinase-2MOFMetal–organic frameworkmPEGMethoxy polyethylene glycolMPRMacrophage polarization regulationmRNAMessenger RNAmTORMechanistic target of rapamycinNF-κBNuclear factor kappa BNIA2-(2-nitroimidazol-1-yl)acetic acidNKNatural killerNPsNanoparticlesNVsNanovesiclesOmOxymatrineOXOxaliplatin prodrugPAH-CitPoly(allylamine hydrochloride)-citraconic anhydridePAMAMPoly(amidoamine)PBAPhenylboronic acidPBSPhosphate-buffered salinePCaProstate cancerPD-1Programmed cell death protein 1PD-L1Programmed death-ligand 1PDACPancreatic ductal adenocarcinomapDNAPlasmid DNAPDLLAPoly(D,L-lactic acid)PEGPolyethylene glycolPEIPolyethyleneiminePELGPoly(ethyl-L-glutamate)PERProton efflux ratePGC-1αPeroxisome proliferator-activated receptor gamma coactivator-1αPGE2Prostaglandin E2PI3KPhosphoinositide 3-kinasepIL-12Plasmid interleukin-12PLAPoly(lactic acid)PlGFPlacental growth factorPLGAPoly(lactic acid-co-glycolic acid)PLLPoly-L-lysinePmPlatelet membranePPARγPeroxisome proliferator-activated receptor gammaPSMAProstate-specific membrane antigenPTXPaclitaxelPTPN6Protein tyrosine phosphatase non-receptor type 6QTN/QUEquercetinR848resiquimodRg3Ginsenoside Rg3rhIL-2Recombinant human interleukin-2RNARibonucleic acidROSReactive oxygen speciesSCMMesenchymal stem cell membraneSHP-1Src homology 2 domain-containing protein tyrosine phosphatase 1siPD-L1PD-L1-targeting small interfering RNAsiPlGFPlGF-targeting small interfering RNAsiPTPN6PTPN6-targeting small interfering RNAsiRNASmall interfering RNASIRP-αSignal regulatory protein αsiVEGFVEGF-targeting small interfering RNAα-SMAα-smooth muscle actinSTATSignal transducer and activator of transcriptionSTAT3Signal transducer and activator of transcription 3STINGStimulator of interferon genesTAMsTumor-associated macrophagesTBK1TANK-binding kinase 1TCMTraditional Chinese medicineTCRT-cell receptorTGF-β1Transforming growth factor-β1Th1T helper 1Th2T helper 2TILsTumor-infiltrating lymphocytesTLR7/8Toll-like receptor 7/8TMCN,N,N-trimethyl chitosanTMETumor microenvironmentTNBCTriple-negative breast cancerTNFTumor necrosis factorTNF-αTumor necrosis factor-αTPPTriphenylphosphoniumTPZTirapazamineTregsRegulatory T cellsTSATanshinone IIATSRTumor suppression rateVEGFVascular endothelial growth factorZIFZeolitic imidazolate framework List of Abbreviations Dual-Component Nanomedicine Systems Dual-component nanomedicine systems for tumor immunotherapy can be broadly classified into same-type dual-drug nanomedicine systems (eg, dual nucleic acid, dual chemotherapy, and dual traditional Chinese medicine (TCM) nanomedicine systems) and different-type dual-drug nanomedicine systems (eg, protein drug--chemotherapy drug, protein drug-nucleic acid drug, chemotherapy drug-nucleic acid drug, and chemotherapy drug-TCM nanomedicine systems). Dual Nucleic Acid Drug Nanomedicine Systems Nucleic acid drugs are a class of therapeutics based on nucleic acid molecules, primarily including small interfering RNA (siRNA), messenger RNA (mRNA), and plasmid DNA (pDNA).51 By precisely regulating gene expression, these agents have emerged as a key strategy in cancer therapy. However, the clinical efficacy of monotherapy with a single nucleic acid drug remains constrained by factors including tumor heterogeneity, the complexity of the immunosuppressive microenvironment, and the limited number of targets addressed. Dual nucleic acid co-loading strategies may improve therapeutic efficacy by simultaneously modulating complementary pathways and targets. Nevertheless, physical co-loading alone does not necessarily demonstrate therapeutic synergy, which should be supported by appropriate single-cargo and combination controls or formal synergy analysis. Existing nanomedicine systems primarily focus on single-drug delivery. However, distinct nucleic acids, such as DNA and RNA, inevitably differ in their physicochemical properties, including molecular size, topology, charge density, and structural rigidity.52,53 Moreover, nucleic acids are highly susceptible to degradation during delivery, necessitating careful consideration of stability and protective strategies in system design. Furthermore, the intracellular release profiles of different nucleic acids vary considerably, requiring this factor to be incorporated into the initial design of delivery systems (Figure 3).54 For example, siRNA must be released into the cytoplasm to mediate gene silencing, whereas pDNA requires subsequent nuclear entry to achieve transgene expression. Therefore, successful dual nucleic acid delivery requires coordinated cargo protection, intracellular trafficking, and subcellular release rather than simple encapsulation within the same carrier. Multiple challenges facing dual nucleic acid drug delivery and their resolution strategies. Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide, with a relative 5-year survival rate of approximately 18%.55 Immunogene therapy using nucleic acid drugs to modulate the HCC TME can remodel the microenvironment and activate immune effector cells.56 However, immunogene therapy still faces numerous challenges, such as the short half-life of therapeutic siRNA/pDNA, lack of tumor-specific cellular uptake, low intracellular release efficiency, and poor nuclear entry capacity of pDNA. Moreover, different nucleic acid cargos exhibit distinct intracellular destinations and release requirements, making coordinated delivery and controlled release important considerations in dual nucleic acid nanomedicine design. To address the aforementioned issues, Huang et al50 engineered tumor-targeted lipid-dendrimer-calcium-phosphate (TT-LDCP) nanoparticles (NPs) with thymine-functionalized dendrimers (TT-LDCP NPs) co-loaded with interleukin-2 (IL-2) pDNA and programmed death-ligand 1 (PD-L1) siRNA. This system efficiently targeted HCC cells through covalent modification of the HCC-specific tumor-targeting peptide (SP94), enabling precise delivery of therapeutic genes. PD-L1 siRNA relieved immune suppression on T cells by inhibiting PD-L1 expression, whereas IL-2 pDNA promoted IL-2 production and enhanced cytotoxic T-cell activation. In addition, TT-LDCP NPs promoted dendritic-cell activation through innate immune stimulation, thereby further enhancing antitumor immunity. Experimental results showed that TT-LDCP-mediated co-delivery of PD-L1 siRNA and IL-2 pDNA significantly increased tumor-infiltrating CD8⁺ T cells compared with either single-cargo treatment. In the orthotopic HCC model, the dual-cargo formulation reduced the mean tumor volume by approximately 74% compared with the control group (approximately 60 vs 230 mm3) and decreased the mean number of lung metastatic nodules from approximately nine to fewer than one. No evident systemic toxicity was observed, as indicated by unchanged hepatic enzyme levels and the absence of histopathological abnormalities in major organs. The dual-nucleic-acid immunogene therapy also sensitized HCC to a granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting whole-cell vaccine. When combined with the vaccine, tumor-infiltrating CD8⁺ T cells increased to approximately threefold and twofold the levels observed in the control and vaccine-only groups, respectively, accompanied by enhanced tumor-specific T-cell activation and improved therapeutic efficacy.57 In the breast cancer microenvironment, vascular endothelial growth factor (VEGF) and placental growth factor (PIGF) are overexpressed and exert synergistic effects on tumor progression and immune suppression. VEGF inhibitors, PIGF inhibitors, and others have demonstrated certain anti-breast cancer effects in clinical settings. However, the efficacy of using a single inhibitor alone is limited due to compensatory mechanisms among multiple factors within the breast cancer microenvironment.58 Studies have indicated that combined administration of VEGF siRNA (siVEGF) and PIGF siRNA (siPIGF) can inhibit angiogenic signaling and remodel the immunosuppressive TME by regulating macrophage polarization.59 Specifically, dual VEGF/PIGF silencing can reduce M2-like tumor-associated macrophages (M2-TAMs) and promote a more immunogenic tumor microenvironment. Song et al60 developed a two-stage pH-responsive multifunctional nanomedicine system (PEG-MT/PC NPs) that co-delivers siVEGF and siPIGF to M2-TAMs and breast cancer cells through active and passive targeting, respectively. In the acidic TME (pH~6.5), M2-TAMs actively internalized this system via mannose receptor-mediated endocytosis, while breast cancer cells passively internalized it through charge-mediated endocytosis. Upon cellular internalization, the anionic poly(allylamine hydrochloride)-citraconic anhydride (PAH-Cit, PC) underwent hydrolysis and charge reversal in acidic late endosomes/lysosomes, thereby facilitating endosomal/lysosomal escape and cytoplasmic siRNA release. Dual siRNA (siV-P) synergistically inhibited VEGF/PIGF signaling, thereby not only directly suppressing tumor proliferation but also repolarizing M2-TAMs into antitumor M1-TAMs through downregulation of hypoxia-inducible factor-1α (HIF-1α). Experimental results demonstrated that in tumor-bearing mouse models, the combination therapy group utilizing the siV-P nanomedicine system achieved a tumor suppression rate of up to 91.3% (compared to 60.8% for single-target siVEGF and 69.5% for siPIGF), exhibiting the most potent suppression of both primary breast tumors and their lung metastases.60 Collectively, current evidence underscores the considerable potential of dual nucleic acid nanomedicine systems to potentiate cancer immunotherapy. Their therapeutic advantages arise from simultaneous regulation of multiple molecular pathways and remodeling of the immune microenvironment. Compared with single-nucleic-acid strategies, this approach may better address tumor heterogeneity and immune evasion mechanisms. Nevertheless, several critical barriers remain, including the difficulty of precisely controlling the intracellular release ratio and temporal kinetics of distinct nucleic acid cargos, insufficient stability under physiological conditions, and the potential immunogenicity and biosafety concerns associated with nanocarriers. Future development should therefore prioritize optimizing dual-cargo formulations, engineering programmable sequential release strategies, and refining nanoplatforms to enhance overall stability, targeting specificity, and safety, thereby advancing dual nucleic acid immunotherapy from proof-of-concept validation toward mechanism-driven design and clinical translation. Dual Chemotherapy Drug Nanomedicine Systems Over the past several decades, the development of traditional chemotherapeutic drugs has predominantly relied on in vitro models or immunodeficient mouse models, resulting in a significant underestimation of the immune system’s contribution to their antitumor efficacy.61 Recent studies have demonstrated that the effects of chemotherapeutic agents on the TME are multifaceted: prolonged administration of a single chemotherapeutic agent may promote immune evasion by inducing tumor cells to express immunosuppressive molecules,62 whereas certain chemotherapeutics can activate antitumor immune responses by inducing immunogenic cell death (ICD).63 ICD promotes the release of damage-associated molecular patterns, thereby facilitating dendritic-cell maturation, antigen presentation, and cytotoxic T-cell activation. Moreover, combining chemotherapeutic agents with complementary mechanisms may enhance therapeutic efficacy by integrating direct tumor-cell killing with immune activation or attenuation of immunosuppression.64 In this context, advances in nanomedicine delivery technologies not only address the physicochemical limitations of conventional drugs and enhance tumor targeting, but also facilitate synergistic therapeutic effects through concurrent delivery, thereby providing an innovative platform for dual-chemotherapy combination therapy. Cisplatin (CDDP) has been utilized as a primary therapeutic agent for lung cancer.65 Recent studies have shown that combination therapy with metformin (MET) significantly improves therapeutic outcomes in lung cancer through a chemo-immunological synergistic mechanism. Nonetheless, the distinct solubility profiles and pharmacokinetic behaviors of CDDP and MET make precise control of their intratumoral concentrations and ratios highly challenging. The co-delivery of these drugs via a nanomedicine system has the potential to effectively address these challenges. Yang et al66 developed a hydrophilic hyaluronic acid–cisplatin (HA-CDDP) prodrug by conjugating hydrophobic CDDP to negatively charged hyaluronic acid (HA). Concurrently, they engineered an amphiphilic polystyrene–polymetformin (PMet) micellar prodrug by grafting MET onto a positively charged polystyrene backbone. These two prodrugs were subsequently assembled via electrostatic interactions into hyaluronic acid–cisplatin/polystyrene–polymetformin (HA-CDDP/PMet) dual-prodrug co-assembled NPs. At an HA-CDDP-to-PMet mass ratio of 1:1, the nanoparticles enabled coordinated delivery of CDDP and MET and partially addressed their asynchronous pharmacokinetic behavior. The co-delivered formulation increased the proportions of CD4⁺ and CD8⁺ T cells, reduced Treg accumulation, and elevated interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) expression, indicating remodeling of the tumor immune microenvironment. Ultimately, HA-CDDP/PMet NPs achieved a significantly higher tumor inhibition rate (64.8%) and prolonged overall survival in the Lewis lung carcinoma mouse model compared with monotherapy groups (PMet: 26.6%; HA-CDDP: 42.5%).66 Gemcitabine (Gem) and paclitaxel (PTX) exhibit complementary cytotoxic and immunomodulatory effects. Gem can deplete myeloid-derived suppressor cells (MDSCs), whereas PTX can stimulate antigen-presenting cells, thereby contributing to the remodeling of the tumor immune microenvironment.67,68 This combination is particularly relevant to triple-negative breast cancer, which is characterized by a poorly immunogenic “cold” tumor microenvironment and a high risk of postoperative recurrence and metastasis.69 However, the markedly different physicochemical properties and pharmacokinetic behaviors of the two agents make it difficult to maintain a therapeutically effective intratumoral drug ratio. Therefore, a nanomedicine platform capable of protecting both agents and coordinating their delivery at an experimentally optimized ratio may enhance both cytotoxic synergy and antitumor immune activation. Guo et al70 developed integrin-targeting micelles co-loaded with a hydrophobic phosphorylated gemcitabine prodrug (HPG) and paclitaxel (PTX), termed ATN-mG/P, to deliver the two agents at predetermined ratios. Among the tested formulations, micelles with a Gem/PTX molar ratio of 10:1 exhibited the strongest in vitro combination effect, with corresponding IC50 values of 0.4 μM for HPG and 0.07 μM for PTX and a combination index of 0.16. These results pharmacologically validated the selected ratio rather than merely demonstrating physical co-loading. Mechanistically, both agents induced immunogenic cell death, whereas PTX further stimulated antigen-presenting cells and Gem reduced myeloid-derived suppressor cells, thereby providing complementary immune-regulatory effects. At the 10:1 ratio, mG/P increased bone marrow-derived dendritic-cell maturation to 58.6%, compared with 47.4% for mGem. In a postoperative recurrent 4T1 triple-negative breast cancer model, ATN-mG/P prolonged the median survival time from 12 days in the phosphate-buffered saline (PBS) group to 27 days and significantly suppressed tumor recurrence and lung metastasis. Further combination with separately administered NanoCpG increased BMDC maturation to 85.6%, reduced recurrent tumor mass from 0.50 to 0.05 g, decreased intratumoral MDSCs from approximately 40% to below 4%, and rendered three of five mice tumor-free.70 Collectively, the two representative systems indicate that dual-drug nanomedicines can integrate direct tumor-cell killing with tumor immune microenvironment remodeling through ICD induction, dendritic-cell activation, MDSC depletion, and T-cell regulation. However, their immunostimulatory effects remain largely secondary and exhibit relatively limited direct immune specificity. Moreover, differences in physicochemical properties and pharmacokinetic behaviors, together with cumulative toxicity and narrow therapeutic windows, complicate the maintenance of therapeutically effective intratumoral drug ratios and constrain clinical translation. Therefore, future design strategies should prioritize drug combinations with complementary rather than redundant mechanisms of action, experimentally validated synergistic ratios, coordinated pharmacokinetics, and intelligent delivery platforms capable of precise ratio control and programmable release. The incorporation of immunomodulatory functionalities may further facilitate the transition of dual-drug nanomedicines from simple physical co-loading toward rational, mechanism-driven, and TME-oriented chemoimmunotherapy. Dual TCM Nanomedicine Systems TCM offers a unique therapeutic perspective in tumor immunotherapy. Compared with conventional chemotherapy drugs, the bioactive constituents of TCM have attracted considerable global research interest due to their multitarget properties and relatively low toxicity.71 However, the therapeutic efficacy of TCM-derived active compounds is often limited by poor bioavailability, inadequate tissue distribution, and complex metabolic processes,72 which collectively hinder their full therapeutic potential. Nanomedicine systems are generally considered effective solutions to these challenges. Notably, the formulation ratios of TCM components critically influence their therapeutic efficacy. However, in the development of dual-TCM synergistic therapeutic systems, disparities in physicochemical properties—including solubility, molecular weight, and stability—among active TCM constituents make controlled-ratio co-loading within nanomedicine systems highly challenging.73,74 Consequently, the development of innovative delivery systems capable of controlled co-loading and coordinated delivery of dual TCM components has emerged as a critical bottleneck in synergistic therapy. As previously mentioned, HCC is considered one of the most challenging cancer types with a poor prognosis.75,76 In recent years, immune checkpoint inhibitors, particularly programmed cell death protein 1 (PD-1) inhibitors, have demonstrated potential in the treatment of HCC.77 However, their objective response rate remains suboptimal at only approximately 15%–20%.78 This is primarily attributed to insufficient levels of tumor-infiltrating lymphocytes (TILs) and their impaired mitochondrial function.79 Oxymatrine (Om), a soluble alkaloid derived from Sophora flavescens, inhibits tumor-associated fibroblast (CAF) activation, thereby enhancing TIL infiltration.80,81 Astragaloside IV (As), an insoluble tetracyclic triterpenoid derived from Astragalus mongholicus, improves mitochondrial function in TILs by upregulating peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) expression.82,83 Therefore, the combined use of Om and As is expected to synergistically enhance both the number and activity of TILs. However, due to significant polarity differences and poor bioavailability, Om and As face challenges in achieving efficient co-loading and targeted delivery in traditional nanomedicine systems, severely limiting their combined application. To overcome these delivery bottlenecks, a previous study84 developed a platelet membrane (Pm)-coated magnetic metal–organic framework (Fe3O4@MIL-100 MOF) nanoplatform for the co-delivery of Om and As (PmMN@Om&As). The porous Fe3O4@MIL-100 MOF enabled co-loading of the two drugs at an approximately 2:1 mass ratio, with individual loading capacities of 22.37 and 11.40 wt% and a total drug-loading capacity of 33.77 wt%. The two cargos also exhibited closely matched release profiles under reductive and acidic conditions (52.32% for Om and 51.38% for As after 72 h), supporting coordinated rather than merely physical co-loading. The Pm coating reduced mononuclear phagocyte system clearance through the CD47-mediated “don’t eat me” signal, whereas magnetic guidance and Pm–collagen interactions enhanced HCC accumulation (Figure 4F). Consistently, in vivo, ex vivo, and tumor tissue fluorescence imaging showed enhanced tumor accumulation of PmMN@DiD under magnetic guidance (Figure 4A–C and E), with a 4.90-fold higher tumor fluorescence intensity than free DiD at 24 h (Figure 4D). In the tumor microenvironment, Om suppressed CAF activation and increased TIL infiltration, whereas As, together with Fe2+/Fe3+ released from the carrier, improved TIL mitochondrial function. Accordingly, combination treatment with PmMN@Om&As and αPD-1 increased CD3+ TIL abundance by 4.10-fold relative to the model group and enhanced TIL proton efflux rate by 7.00-fold relative to αPD-1 monotherapy. Therapeutically, this combination achieved an 84.15% tumor suppression rate, reduced tumor volume by 4.69-fold relative to αPD-1 alone, and prolonged the median survival time to 38 days.84 Biodistribution of PmMN@Om&As. The distribution of free DiD, MN@DiD, PmMN@DiD, PmMN@DiD, and magnetic field in HCC mice were visualized by IVIS Spectrum (A). After 24 h, the ex vivo imaging of various organs (B) and tumor tissues (C) was observed by the IVIS Spectrum. The ex vivo imaging of tumor tissue was analyzed (D) (n = 3). The distribution of free DiD, MN@DiD, PmMN@DiD, PmMN@DiD, and magnetic field in tumor tissue was observed by confocal laser microscopy (scale bar = 200 μm) (E). The adhesion ability of collagen to PmMN@Om&As was shown by fluorescence microscopy (scale bar = 20 μm) (F). Data are represented as the means ± SD *p < 0.05, two-tailed Student’s t test. Reproduced from Guo et al84 under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. Similarly, Guo et al85 combined tanshinone IIA (TSA) with As to simultaneously enhance the abundance and activity of TILs in HCC. TSA promotes tumor vascular normalization by suppressing VEGF, thereby facilitating TIL infiltration,86 whereas As alleviates the immunosuppressive microenvironment and enhances TIL activity.87 However, the poor aqueous solubility and limited bioavailability of both compounds hinder their efficient co-delivery to HCC tissues.88 To address these limitations, a homologous H22 cell membrane-coated magnetic Fe3O4@MIL-100 MOF nanoplatform (Hm@TSA/As-MOF) was developed for the co-delivery of TSA and As (Figure 5A). The MOF enabled efficient co-loading of TSA and As, with a total drug-loading capacity of 16.13 wt%, and showed comparable release profiles for both drugs under acidic and reductive conditions, supporting tumor-microenvironment-responsive co-delivery. Representative design, biodistribution, immune modulation, and therapeutic efficacy of Hm@TSA/As-MOF combined with αPD-1 for HCC treatment. (A) Schematic illustration of the combination therapy of Hm@TSA/As-MOF and αPD-1 in HCC. (a) Preparation of Hm@TSA/As-MOF by loading TSA and As into Fe3O4@MIL-100 MOFs followed by homologous tumor cell membrane coating. (b) Homologous membrane-mediated immune escape and homologous targeting, together with magnetic guidance, enhanced targeting of solid tumors. (c) Tumor-microenvironment-responsive release of TSA and As, with TSA increasing TIL abundance through tumor vascular normalization and As enhancing TIL activity by reducing immunosuppressive factors. (d) Combination of Hm@TSA/As-MOF with αPD-1 enhanced the overall anti-HCC effect. (B) In vivo biodistribution of free DiD (I), DiD-MOF (II), Hm@DiD-MOF (III), and Hm@DiD-MOF with magnetic guidance (IV) in orthotopic HCC-bearing mice. (C and D) Flow cytometric analysis of CD3+ TILs (C) and CD8+ TILs (D) in tumor tissues following different treatments. (E) Quantitative analysis of tumor fluorescence intensity. (F) Tumor suppression rate (TSR) after different treatments. (G) Survival curves of HCC-bearing mice. Data are expressed as the mean ± SD (*p<0.05, **p<0.01, ***p<0.001 based on two-tailed Student’s t-test). Adapted and rearranged from Guo et al85 under a Creative Commons Attribution 4.0 International License. The homologous membrane coating provided immune-evasive and homotypic targeting properties, while magnetic guidance further enhanced the accumulation of the nanoplatform in solid HCC tissues despite interference from tumor cells in ascites (Figure 5B and E). When combined with αPD-1, Hm@TSA/As-MOF promoted tumor vascular normalization and markedly increased TIL infiltration; CD3+ TIL abundance increased by 2.60-fold, whereas CD8+ and CD4+ TILs increased by 4.81- and 4.04-fold, respectively, relative to the model group (Figure 5C and D). The treatment also reduced TGF-β1, IL-6, and IL-10 levels and enhanced T-bet/Eomes expression and the production of IFN-γ and granzyme B in CD8+ TILs, indicating improved antitumor T-cell activity. Consequently, the combination therapy achieved a tumor suppression rate of 79.18%, reduced tumor volume to 26.20% of that observed with αPD-1 monotherapy, and prolonged the median survival time to 32 days (Figure 5F and G).85 TCM holds broad application prospects in immune-mediated antitumor therapy, particularly with recent discoveries that its active components can activate antitumor immune responses by ICD. ICD activates dendritic cells (DCs) by releasing damage-associated molecular patterns, thereby inducing T cell-mediated antitumor immune responses. However, the efficacy of ICD is constrained by the immunosuppressive properties of the TME, particularly the inefficient antigen presentation resulting from insufficient reactive oxygen species (ROS) levels.89 Ginsenoside Rg3 (Rg3), a triterpenoid derived from Panax ginseng, has been shown to induce ICD in tumor cells by activating autophagy and endoplasmic reticulum stress pathways.90 Similarly, quercetin (QTN), a flavonoid ROS inducer derived from Sophora japonica seeds, enhances apoptosis by upregulating the BAX–caspase pathway and downregulating BCL-2, thereby synergizing with Rg3.91 Although the combination of Rg3 and QTN exhibited a favorable synergistic effect,92 their poor water solubility, insufficient targeting, and low bioavailability restrict their potential therapeutic benefit. To enhance the synergistic immunotherapy effects of Rg3 and QTN, Sun et al93 created polyethylene glycol (PEG)-modified amphiphilic cyclodextrin (CD-PEG-FA/Rg3-QTN) NPs to deliver Rg3 and QTN simultaneously. Through PEGylation and folate (FA)-mediated active targeting, CD-PEG-FA/Rg3-QTN NPs substantially prolonged the circulation time of Rg3 and QTN and enhanced their accumulation in colorectal tumors. The NPs reduced nonspecific tissue distribution by around 3.5 times in the CT26 orthotopic colorectal cancer model. CD-PEG-FA/Rg3-QTN NPs substantially reduced immunosuppressive cell populations (Tregs, myeloid-derived suppressor cells [MDSCs], and M2-TAMs), increased immunostimulatory cells (CD8+ T cells, CD4+ T cells, and activated DCs), and decreased IL-4, IL-6, and IL-10 levels. Furthermore, CD-PEG-FA/Rg3-QTN NPs significantly enhanced therapeutic efficacy when combined with anti-PD-L1 antibodies, increasing tumor cell apoptosis rates from 11% to 27% (compared to 0.7% in the PBS group and 1.1% in the anti-PD-L1 group).93 Collectively, dual traditional Chinese medicine (TCM)-based nanomedicine systems represent an important and innovative strategy for cancer immunotherapy by leveraging the multitarget synergistic properties of bioactive TCM components. Nevertheless, this approach also faces several TCM-specific challenges, including variability in the origins of active constituents, insufficient batch-to-batch consistency, complex metabolic behaviors, and difficulties in quality standardization, all of which substantially increase the complexity of mechanistic elucidation, efficacy evaluation, and standardized application. Accordingly, future design strategies should place greater emphasis on mechanism-oriented optimization and standardized integration by incorporating dynamic monitoring of the tumor microenvironment (TME) together with robust quality control frameworks for TCM-based combinations. Such efforts are essential for advancing dual TCM nanomedicine systems from empirical compatibility toward quantitative, reproducible, and rationally engineered paradigms with greater practical value. Antibody - Nucleic Acid Drug Nanomedicine Systems As core components of immunotherapy, antibodies enhance antitumor immune responses by specifically recognizing immune checkpoint molecules (eg, PD-1/PD-L1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)) and tumor-associated antigens, thereby modulating immune responses through multiple mechanisms. Meanwhile, nucleic acid drugs, as a cornerstone of gene therapy, provide synergistic benefits to immunotherapy by enhancing immune cell function, reversing immunosuppressive microenvironments, inducing durable immune memory, and overcoming therapeutic resistance.94 Therefore, combining antibodies with nucleic acid therapeutics holds considerable promise for synergistically enhancing immunotherapeutic efficacy while overcoming the limitations associated with monotherapy.95 Building upon this foundation, the rational design of efficient and stable delivery vehicles may substantially improve the stability, targeting capability, and transfection efficiency of nucleic acid therapeutics while simultaneously potentially reducing antibody off-target effects and enhancing tumor accumulation, thereby facilitating synergistic integration of immunotherapy and gene therapy. Nonetheless, the co-loading of antibodies and nucleic acid drugs presents multiple challenges. First, nucleic acid therapeutics and antibodies differ substantially in physicochemical properties, including molecular weight, charge polarity, and aqueous solubility. These disparities complicate the construction of co-loading systems.96 Second, TME heterogeneity influences in vivo drug penetration and accumulation, thereby necessitating delivery platforms capable of coordinating the release kinetics of co-loaded agents to avoid suboptimal efficacy caused by asynchronous release.97–99 Third, balancing carrier biocompatibility with immune-activating efficacy is essential to prevent toxicities arising from excessive immune stimulation.97,100 To address these challenges, Lin et al101 engineered an exosome-based nanomedicine system (Exo-PEG-PEI-PD/siRNA) for the co-delivery of anti-PD-L1 antibody and siRNA (Figure 6). This system utilized the amphiphilic polymer polyethylene glycol–polyethyleneimine (PEG-PEI) to modify the exosome surface, thereby imparting a positive charge that facilitated electrostatic adsorption of negatively charged siRNA. Simultaneously, PEG extended the circulation time of the system within the bloodstream. PD-L1 antibody modification not only enabled active tumor targeting but also functioned as an immune checkpoint inhibitor to reverse the immunosuppressive TME, thereby enhancing TIL-mediated antitumor immunity. The final nanocomplex achieved a siRNA loading efficiency of 93.75%, with significantly enhanced release under acidic TME conditions (pH 6.0) relative to physiological pH (91.8% vs 60%). The complex was internalized through antibody-mediated cellular uptake. The siRNA effectively silenced PD-L1 gene expression, while the PD-L1 antibody on the vector surface simultaneously blocked immunosuppressive signals. This dual intervention synergistically activated the antitumor immune response. Experimental findings demonstrated that PD-L1 antibody-modified Exo-PEG-PEI-PD/siRNA exhibited significantly greater uptake efficiency in lung cancer cells (A549/H460) than the non-targeted control. This targeted complex achieved a tumor cell proliferation inhibition rate of up to 50% within 24 hours, substantially surpassing the performance of the non-targeted group. It simultaneously promoted tumor cell apoptosis and reduced clonogenic capacity.101 Preparation and anti-tumor immune response diagram of Exo-PEG-PEI-PD/siRNA co-delivered nanomedicine system.101 Although integrating antibodies and nucleic acid therapeutics within a single nanoplatform conceptually enables extracellular immune checkpoint blockade and intracellular gene regulation, most current systems remain largely confined to the level of “co-delivery” and have yet to fundamentally resolve the critical issue of mechanistic synchronization. Antibodies primarily exert receptor-blocking functions at the cell membrane or within the tumor stroma, whereas siRNA must undergo cellular internalization, endosomal escape, and cytoplasmic release before achieving effective gene silencing. Consequently, these two modalities exhibit inherent differences in therapeutic targets, temporal scales, and biological kinetics. In addition, existing studies have predominantly focused on drug loading capacity or mass ratio as primary evaluation metrics; however, in antibody–nucleic acid nanomedicine systems, a more biologically meaningful determinant may be the functional balance between effective receptor blockade intensity and gene silencing efficiency. This challenge highlights the need for future design strategies to progress beyond conventional co-loading approaches toward quantitative, mechanism-driven integration. Specifically, establishing correlative models linking delivery kinetics with immune activation dynamics may enable systematic optimization of the balance between antibody functional integrity and intracellular nucleic acid delivery efficiency, thereby advancing antibody–nucleic acid nanomedicine systems toward more precise, systemically coordinated immunotherapeutic platforms. Antibody - Chemotherapy Drug Nanomedicine Systems The immunoregulatory efficacy of antibodies in modulating immune cells has substantially contributed to their widespread application in immune-based antitumor therapies.102 Concurrently, chemotherapy drugs not only exert direct cytotoxic effects on tumor cells but also enhance antitumor immune responses by inducing ICD within tumors (Figure 7).103 Nevertheless, chemotherapy drugs generally lack intrinsic targeting capabilities, whereas antibodies, despite possessing target specificity, may still produce unpredictable adverse effects when off-target.104 Schematic illustration of the synergistic antitumor immune mechanism of antibody-chemotherapy co-loaded nanomedicine systems. Chemotherapeutic agents delivered by nanocarriers induce ICD of tumor cells and release tumor antigens; meanwhile, the co-loaded antibodies exert immune modulation effects. The released antigens are presented by DCs to activate T cells, which then migrate to tumor sites and mediate tumor cell killing, collectively achieving enhanced antitumor immunity. In recent years, combinations of chemotherapy drugs and antibodies have increasingly been adopted as first-line therapeutic strategies for various malignancies, including non-small cell and small cell lung cancer, head and neck cancer, and breast cancer.105,106 Additionally, these two therapeutic classes exhibit substantial physicochemical differences: chemotherapy drugs are primarily small-molecule compounds, whereas antibodies are large biomacromolecules that differ markedly in molecular weight and steric properties. Moreover, antibodies, as biological agents, generally exhibit limited stability compared to chemotherapy drugs, which tend to demonstrate enhanced stability.107 Therefore, specially engineered co-loaded nanomedicine systems are required to maximize the synergistic potential of their combined application. The primary antitumor mechanism of PD-L1 antibodies involves inhibition of the PD-1/PD-L1 pathway, thereby restoring T-cell immune function.108 However, insufficient CD8+ T cell infiltration and inadequate maturation of tumor-infiltrating dendritic cells, resulting from the low immunogenicity of the TME, substantially limit the antitumor efficacy of PD-L1 antibodies. Paclitaxel (PTX) not only directly kills tumor cells but also promotes DC maturation and suppresses regulatory T cells (Tregs), thereby indirectly enhancing antitumor immunity.70,109 By inducing ICD in tumor cells, PTX can reshape the TME and synergistically enhance antitumor effects when combined with PD-L1 antibodies. However, PTX exhibits poor aqueous solubility, limited targeting efficiency, and substantial systemic toxicity, whereas PD-L1 antibodies face stability-related challenges. The substantial differences in their physicochemical properties and pharmacokinetics severely limit their synergistic efficacy. Accordingly, combining PD-L1 antibodies with PTX has been proposed as a strategy to achieve superior therapeutic outcomes. Le Minh Pham and colleagues110 engineered pH-responsive NPs for targeted breast cancer therapy. This nanomedicine system was constructed by conjugating PD-L1 antibodies to albumin (PD-L1/PTX@HSA) using nano albumin binding (NAB) technology. Human serum albumin (HSA) was employed for efficient PTX encapsulation. Through dual active targeting mediated by HSA and PD-L1, this nanomedicine system achieved a 3.1-fold increase in NP accumulation within breast cancer xenografts relative to the non-targeted group. It also reduced drug distribution in organs such as the heart and liver, thereby improving PTX targeting and lowering its systemic toxicity. The weakly acidic TME promoted cleavage of the imine bond between PD-L1 and poly-L-lysine (PLL), thereby releasing PD-L1 into the extracellular matrix, where it exerted immunoregulatory functions. Furthermore, the presence of amino groups in PLL imparted a positive charge to the NP surface, enhancing PD-L1/PTX@HSA stability and reducing its clearance by the reticuloendothelial system. Experimental results demonstrated that this nanomedicine system effectively induced apoptosis in breast cancer cells while promoting antigen release. The number of CD8+CD44+ T cells in mice treated with PD-L1/PTX@HSA combined with CTLA-4 was significantly higher (approximately 38%) than in the control group treated with free PTX (approximately 9.25%). This combination also demonstrated the strongest tumor volume and weight suppression effects, exhibiting potent antitumor activity both in vitro and in vivo.110 Doxorubicin (DOX), a conventional chemotherapy drug, can remodel the TME through its potent ICD-inducing capacity. However, it may also induce PD-L1 upregulation in tumor cells as an unintended effect.111 Combining it with PD-L1 antibodies can restore the anti-tumor immune function of effector T cells. Nonetheless, as macromolecular therapeutics, antibodies often exhibit limited tumor penetration.112 Additionally, their pharmacokinetic properties differ significantly from those of hydrophobic small-molecule chemotherapy drugs, often leading to asynchronous in vivo release when administered through traditional combination strategies, which impedes the realization of synergistic effects. Based on this rationale, Liao et al113 proposed a drug delivery strategy integrating anthracycline-loaded DOX nanomedicine with PD-L1 antibodies. In this strategy, PD-L1 antibodies not only enabled targeted delivery to tumor sites but also blocked the PD-1/PD-L1 signaling pathway to exert antitumor immune effects. Concurrently, DOX could induce ICD to further amplify the anti-tumor immune response. The PD-L1 antibody-mediated immune modulation synergized with the DOX-induced ICD effect, forming a virtuous anti-tumor cycle that significantly enhanced antitumor efficacy. Furthermore, to mitigate adverse effects, this nanomedicine system was designed to be acid-responsive, ensuring that drug release predominantly occurred within the acidic TME. This targeted release minimized systemic exposure and reduced toxicity in the bloodstream and normal tissues, thereby decreasing systemic toxicity and immune-related side effects. Experimental results demonstrated that in the CT26 colon cancer mouse model, the acid-responsive nano co-delivery group achieved an estimated tumor growth inhibition rate of approximately 67%, and exhibited significantly superior antitumor efficacy compared with all other control groups. Notably, 50% of mice in the free doxorubicin plus anti-PD-L1 antibody combination group died of acute immune-related adverse events on day 15 post-tumor inoculation. In contrast, no treatment-related mortality was observed in the nano co-delivery group, where mice maintained stable body weight and showed no obvious histopathological abnormalities in major organs. Consistently enhanced antitumor efficacy was also validated in the B16F10 melanoma model, confirming the broad applicability of this acid-responsive co-delivery strategy across different tumor types.113 Antibody - TCM Nanomedicine Systems Low antigen expression within tumor tissues is a key factor contributing to the limited antitumor efficacy of immune checkpoint-related antibodies.114 Recent studies have demonstrated that bioactive TCM-derived compounds, such as astragaloside IV and curcumin, can enhance tumor antigen exposure by inducing ICD within tumors.115,116 Their multicomponent synergistic interactions with antibodies in immune regulation can further reshape the TME. Consequently, co-loading immune checkpoint antibodies with bioactive TCM-derived compounds within nanomedicine systems offers significant therapeutic advantages in cancer treatment (Table 2). Table 2Composition, Characteristics and Immune Activation Mechanisms of Nanomedicine Systems Co-Loaded with Antibody and TCMAntibodyTCMNanocarrierCo-Loading SystemCharacteristicsImmune Activation PathwayKey Immune Cells InvolvedReferencesAtezolizumabDihydrotanshinone I (DHT)Polymeric nanoparticlesAtezolizumab-conjugated DHT-loaded polymeric nanoparticles (ATEZO-DHT NPs)1. PD-L1 receptor-mediated endocytosis for targeted tumor delivery.2. Sustained drug release profile.3. Synergistic ICB + ICD effect with negligible systemic toxicityDHT induces immunogenic cell death to release tumor-associated antigens; anti-PD-L1 antibody blocks the PD-1/PD-L1 immune checkpoint axis; the two synergistically amplify antitumor immunity.CD4+ T cells, CD8+ cytotoxic T cells[117]αPD-L1Rg3R6F3 peptide-modified chitosan nanoparticles in a thermosensitive PPP hydrogelRg3-loaded permeation-enhancing nanoparticles and doxorubicin co-encapsulated in a local thermosensitive hydrogel, combined with αPD-L11. Local hydrogel depot enabled sustained release and enhanced tumour permeation.2. Rg3 nanoparticles strengthened doxorubicin-induced immunogenic cell death.3. Controlled both treated and distant tumours and promoted immune memory.Rg3-loaded nanoparticles enhance doxorubicin-induced calreticulin exposure and ATP/HMGB1 release, promoting dendritic-cell maturation and converting 4T1 tumours from cold to hot. αPD-L1 further increases T-helper-1 and cytotoxic T-cell responses, decreases regulatory T cells and supports effector-memory T-cell formation.Mature dendritic cells; CD4+IFN-γ+ T-helper-1 cells; CD8+IFN-γ+ cytotoxic T cells; regulatory T cells; effector-memory T cells[118]αPD-L1Dihydroartemisinin (DHA)Zinc-pyrophosphate core-shell nanoparticlesCholesterol-DHA derivative and pyropheophorbide-iron co-delivered in ZnP@Chol-DHA/Pyro-Fe nanoparticles, combined with αPD-L11. Co-delivery of a DHA prodrug and an iron photosensitiser.2. Amplified iron- and reactive-oxygen-species-dependent lipid peroxidation.3. Sensitised poorly immunogenic colorectal tumours to checkpoint blockade.The nanomedicine induces ferroptotic tumour-cell death through iron-dependent lipid peroxidation and increases calreticulin exposure and HMGB1 release. The resulting immunogenic signals prime T-cell responses and increase intratumoral CD8+ T-cell infiltration, thereby potentiating αPD-L1 therapy.CD8+ T cells[119]αPD-1Gambogic acid (GA)CT26 cancer-cell-membrane-coated PLGA nanoparticlesGA-loaded PLGA nanoparticles coated with homologous tumour-cell membrane (CCM-PLGA/GA), combined with separately administered αPD-11. Combined GA-mediated tumour killing/adjuvanticity with homologous tumour antigens.2. Cancer-cell-membrane coating improved stability, circulation and tumour targeting.3. Functioned as a therapeutic nanovaccine and enhanced αPD-1 efficacy.The homologous cancer-cell membrane provides tumour-associated antigens, whereas GA contributes direct tumour killing and immunoadjuvant activity. CCM-PLGA/GA promotes dendritic-cell maturation and a favourable immune microenvironment; αPD-1 relieves checkpoint inhibition to strengthen CD8+ T-cell-mediated antitumour immunity.Dendritic cells; CD8+ T cells[120]PD-1 protein (surface-expressed on nanovesicles)Curcumin (CUR)PLGA nanoparticles coated with genetically engineered PD-1-overexpressing nanovesiclesPDI@Cur-PLGA (PD-1 NV-coated curcumin-loaded PLGA NPs)1. Integrates ICD and ICB therapy into one nanosystem.2. Genetically engineered NVs improve tumor targeting.3. Low-cost, safe and effective synergistic strategy.Curcumin induces tumor apoptosis and activates ICD via inhibiting NF-κB and Bcl-2, activating caspase/Bax signaling; PD-1 on NVs blocks the PD-1/PD-L1 pathway; synergistically enhances intratumoral infiltration of mature DCs and CD8+ T cells.Mature dendritic cells, CD8+ cytotoxic T cells[121]αPD-L1CURM2pep-functionalised chitosan nanoparticlesM2pep-Cs-Cur nanoparticles combined with separately administered αPD-L11. M2pep-mediated selective uptake by M2-like tumour-associated macrophages.2. pH-dependent Cur release and macrophage-directed delivery.3. Improved therapeutic response and survival with αPD-L1 in triple-negative breast cancer.Targeted Cur delivery downregulates COX-2 in M2-like tumour-associated macrophages and drives M2-to-M1 repolarisation, with reduced CD163 and IL-10 and increased CD80, CD86 and IL-1beta. Reprogramming the macrophage compartment relieves immunosuppression and increases the response to αPD-L1 therapy.M2-like tumour-associated macrophages; M1-like tumour-associated macrophages[122]αPD-1CURReversibly disulfide-cross-linked mPEG-PLA-(LA)4 telodendrimer micellesCur-loaded disulfide-cross-linked micelles (Cur/DCMs) combined with separately administered αPD-11. Blood-stable micelles with slow extracellular Cur release.2. Glutathione-accelerated release under reducing conditions.3. Synergistic tumour suppression in the MC-38 colorectal tumour model.Cur/DCMs improve intratumoral Cur exposure through nanoparticle accumulation and reductive intracellular release. The original study concluded that Cur/DCMs reversed the immunosuppressive tumour microenvironment and thereby potentiated αPD-1 therapy; a specific immune-cell mechanism was not experimentally resolved.No specific immune-cell subset was quantitatively profiled in the study.[123]αPD-L1LuteolinStealth PLGA/liposome hybrid nanoparticlesPD-L1 antibody-targeted PLGA/liposomes loaded with luteolin (L-PD-SP/Ls)1. PD-L1-mediated active tumor targeting.2. Enhanced cellular uptake compared with non-targeted NPs.3. Effectively inhibits liver cancer cell proliferation with low carrier cytotoxicity.Luteolin directly suppresses tumor cells via downregulating Bcl-2 and increasing LDH release; αPD-L1 antibody mediates targeted delivery and contributes to immune checkpoint blockade.No specific immune cell subsets investigated; focus on targeted delivery and cytotoxicity[124]αPD-1Ginseng-derived nanoparticles (GDNPs)Plant-derived extracellular vesicle-like nanoparticlesGDNPs combined with αPD-11. Biocompatible natural nanoparticles suitable for systemic immune modulation.2. Converted an immunologically cold tumour microenvironment into a T-cell-inflamed state.3. Enhanced checkpoint-blockade efficacy and generated durable systemic antitumour immunity.GDNPs reprogramme tumour-associated macrophages to increase CCL5 and CXCL9 secretion. These chemokines recruit CD8+ T cells into tumours, converting the cold tumour microenvironment into a hot microenvironment and increasing responsiveness to αPD-1 therapy.M1-type tumor-associated macrophages, CD8+ cytotoxic T cells[125]αPD-L1Allium sativum (garlic)-derived nanoparticles (GNPs)Natural garlic-derived nanoparticles obtained by differential centrifugationOrally administered GNPs combined with separately administered αPD-L11. Oral, plant-derived nanomedicine that activates endogenous immunity.2. Established a gut-to-tumour immune axis without ex vivo cell expansion.3. Synergised with αPD-L1 to induce robust antitumour immunity.Oral GNPs expand and activate intestinal gamma-delta T cells, resulting in abundant interferon-gamma production. GNP treatment also increases CXCR3 expression on intestinal gamma-delta T cells, driving their migration from the gut to tumours; translocated cells and interferon-gamma remodel the tumour immune microenvironment and enhance αPD-L1 efficacy.Intestinal and tumour-infiltrating gamma-delta T cells[126]Abbreviations: ATEZO, atezolizumab; ATP, adenosine triphosphate; CCL5, C-C motif chemokine ligand 5; CCM, cancer cell membrane; COX-2, cyclooxygenase-2; CUR, curcumin; CXCL9, C-X-C motif chemokine ligand 9; CXCR3, C-X-C motif chemokine receptor 3; DCs, dendritic cells; DCMs, disulfide-cross-linked micelles; DHA, dihydroartemisinin; DHT, dihydrotanshinone I; GA, gambogic acid; GDNPs, ginseng-derived nanoparticles; GNPs, garlic-derived nanoparticles; HMGB1, high mobility group box 1; ICB, immune checkpoint blockade; ICD, immunogenic cell death; IFN-γ, interferon-γ; IL-1β, interleukin-1β; IL-10, interleukin-10; LDH, lactate dehydrogenase; mAb, monoclonal antibody; mPEG, methoxy polyethylene glycol; NF-κB, nuclear factor kappa B; NPs, nanoparticles; NVs, nanovesicles; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PLA, poly(lactic acid); PLGA, poly(lactic acid-co-glycolic acid); PPP, thermosensitive PPP hydrogel; Rg3, ginsenoside Rg3; ROS, reactive oxygen species. Composition, Characteristics and Immune Activation Mechanisms of Nanomedicine Systems Co-Loaded with Antibody and TCM Abbreviations: ATEZO, atezolizumab; ATP, adenosine triphosphate; CCL5, C-C motif chemokine ligand 5; CCM, cancer cell membrane; COX-2, cyclooxygenase-2; CUR, curcumin; CXCL9, C-X-C motif chemokine ligand 9; CXCR3, C-X-C motif chemokine receptor 3; DCs, dendritic cells; DCMs, disulfide-cross-linked micelles; DHA, dihydroartemisinin; DHT, dihydrotanshinone I; GA, gambogic acid; GDNPs, ginseng-derived nanoparticles; GNPs, garlic-derived nanoparticles; HMGB1, high mobility group box 1; ICB, immune checkpoint blockade; ICD, immunogenic cell death; IFN-γ, interferon-γ; IL-1β, interleukin-1β; IL-10, interleukin-10; LDH, lactate dehydrogenase; mAb, monoclonal antibody; mPEG, methoxy polyethylene glycol; NF-κB, nuclear factor kappa B; NPs, nanoparticles; NVs, nanovesicles; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PLA, poly(lactic acid); PLGA, poly(lactic acid-co-glycolic acid); PPP, thermosensitive PPP hydrogel; Rg3, ginsenoside Rg3; ROS, reactive oxygen species. Atezolizumab (ATEZO) is a PD-L1-targeting monoclonal antibody that has received FDA approval for the treatment of various hematologic malignancies and solid tumors.127 Dihydrotanshinone I (DHT), a bioactive constituent derived from Danshen (Salvia miltiorrhiza), can induce ICD and enhance antitumor immune responses.128 DHT therefore holds potential to synergistically augment the antitumor immunotherapeutic effects of ATEZO. Nonetheless, DHT faces several limitations, including inadequate targeted biodistribution, significant systemic toxicity, and suboptimal synergistic delivery efficiency when combined with antibody therapeutics. To address these challenges, Wang et al117 engineered NPs co-loaded with ATEZO and DHT (ATEZO-DHT NPs) using a hypoxia-sensitive diblock copolymer, poly(lactic acid-co-glycolic acid)-p-aminoazobenzene-poly(ethylene glycol) (PLGA-Azo-PEG). ATEZO was chemically conjugated to the NP surface, whereas DHT was encapsulated within the hydrophobic core as an ICD-inducing therapeutic agent. The particle size of this nanomedicine system (246.9 ± 10.23 nm) enabled passive tumor targeting through the enhanced permeability and retention (EPR) effect. Concurrently, surface-bound ATEZO specifically bound to PD-L1 on tumor cells, thereby enabling active targeting. Subsequently, under hypoxic TME conditions, cleavage of the azobenzene bond within PLGA-Azo-PEG triggered DHT release, thereby inducing tumor cells to release damage-associated molecular patterns. This process enhanced DC maturation and promoted CD8+ and CD4+ T cell infiltration, thereby synergistically augmenting antitumor immunity. Cleavage of the azobenzene bond simultaneously releases ATEZO, which then activates antitumor T-cell responses. In vitro, ATEZO-DHT NPs exhibited the strongest hypoxia-responsive cytotoxicity against HGC-27 cells, reducing the IC50 by approximately 63% relative to DHT NPs under hypoxic conditions (0.125 vs 0.341 μM). In vivo, in immunocompetent MFC tumor-bearing mice, the intratumoral proportions of CD4⁺ and CD8⁺ T cells following ATEZO-DHT NP treatment were 2.37 and 1.84 times those in the DHT NP group, respectively. ATEZO-DHT NPs also reduced the intratumoral Treg proportion by approximately 30% relative to DHT NPs (approximately 26% vs 38%). These immune changes were accompanied by a tumor suppression rate approximately 1.3 times that of DHT NPs (approximately 66% vs 50%).117 Anti‑PD‑1 monoclonal antibody (αPD‑1) represents a cornerstone of cancer immunotherapy, yet its clinical benefit in microsatellite‑stable colorectal cancer remains modest due to the immunosuppressive “cold” tumor microenvironment and insufficient tumor antigen presentation.129 Gambogic acid (GA), a natural bioactive xanthone derived from Garcinia hanburyi, exerts direct cytotoxicity and immune‑modulatory effects by inhibiting VEGF‑mediated angiogenesis and promoting DC activation,130 but its poor aqueous solubility and systemic toxicity limit its application as an immune adjuvant.131 To address these limitations, Huang et al120 constructed a cancer cell membrane‑coated nano‑vaccine (CCM‑PLGA/GA NPs, CPG NPs) by coating CT26 colon cancer cell membranes onto GA‑loaded PLGA cores. The cancer cell membrane shell endowed nanoparticles with homotypic tumor targeting, immune evasion from reticuloendothelial clearance, and endogenous tumor‑associated antigens, while encapsulated GA functioned as an immune adjuvant to amplify DC activation. With an average diameter of approximately 182 nm, these nanoparticles accumulated in tumor tissues via the EPR effect combined with homotypic recognition. Upon internalization, released GA promoted DC maturation, which cross‑presented tumor antigens to prime CD8+ T‑cell responses. When combined with αPD‑1, this nano‑vaccine further reversed T‑cell exhaustion and exerted robust synergistic antitumor immunity. In vitro, CPG NPs enhanced the maturation of bone marrow‑derived DCs (CD11c+CD86+) by approximately 4‑fold relative to the control group, outperforming non‑membrane‑coated PLGA/GA NPs. CPG NPs also exhibited significantly higher cellular uptake in homotypic CT26 cells and reduced phagocytosis by macrophages, confirming the advantages of membrane camouflage. In vivo, in CT26 tumor‑bearing BALB/c mice, CPG NP treatment increased intratumoral CD8+ T‑cell infiltration by more than 2‑fold compared with the saline group. The combination of CPG NPs with αPD‑1 achieved the strongest tumor growth suppression, with an estimated tumor growth inhibition rate of approximately 83% on day 18 post‑tumor inoculation. This combination also markedly reduced the Ki‑67 proliferation index in tumor tissues. No significant body weight loss or histopathological damage to major organs was observed, indicating favorable biosafety.120 Chemotherapy Drug - Nucleic Acid Drug Nanomedicine Systems Recently, combinatorial strategies integrating gene therapy with chemotherapy have gained increasing prominence in solid tumor research owing to their potential synergistic therapeutic effects. For instance, siRNA can precisely target messenger RNA to mediate PD-L1 gene silencing, thereby potentially overcoming resistance associated with protein mutations. When combined with chemotherapy drugs, this approach may produce synergistic therapeutic outcomes. However, traditional chemotherapy drugs are predominantly hydrophobic small molecules, whereas nucleic acid drugs are highly hydrophilic macromolecules. The physicochemical disparities between these two classes of drugs pose significant challenges for traditional delivery systems in achieving co-loading and synergistic delivery. Consequently, the development of a nanocarrier system that enables the concurrent delivery of chemotherapy drugs and nucleic acid drugs, while enhancing tumor targeting efficacy and regulating intracellular release, represents a significant challenge that necessitates urgent resolution.132,133 In the immunotherapy of prostate cancer bone metastases, although DOX can induce ICD and antigen release, it may also exacerbate immune suppression by upregulating PD-L1 expression. PD-L1 siRNA (siPD-L1) can suppress PD-L1 expression, thereby counteracting the immunosuppressive microenvironment. Combining siPD-L1 with DOX could create a dual-regulation mechanism: DOX triggers ICD and antigen release, while siPD-L1 precisely suppresses PD-L1 upregulation, thereby exerting an anti-tumor immune effect. However, the highly anionic nature of siPD-L1 causes electrostatic repulsion with cell membranes and the tumor stroma, thereby reducing cellular uptake. Meanwhile, its large molecular weight hinders penetration of dense tumor stroma, differing pharmacokinetically from chemotherapeutics, necessitating an efficient delivery system for synergistic therapy. To address this issue, Mu et al134 engineered poly(dopamine) (PDA) NPs enveloped with mesenchymal stem cell membranes (SCM) to co-deliver DOX and siPD-L1 (PDA-DOX/siPD-L1@SCM) for treatment of prostate cancer (PCa) bone metastases. This system exploited the hydrophobic π-conjugated backbone of PDA NPs for the efficient loading of DOX, while the surface-abundant amino and phenolic hydroxyl groups facilitated the electrostatic adsorption of negatively charged siRNA, thereby achieving the co-loading of both hydrophilic and hydrophobic drugs. PDA-DOX/siPD-L1@SCM targeted tumors via membrane-surface chemokine receptors on the SCM coating, thereby mitigating the risk of cardiac accumulation associated with free DOX. Simultaneously, the immune camouflage properties of SCM significantly diminished clearance by the mononuclear phagocyte system, thereby extending the circulation time of the NPs. At prostate tumor sites, DOX facilitated tumor cell ICD, thereby augmenting antigen release, whereas siPD-L1 downregulated PD-L1 expression, thereby mitigating immune suppression. Experimental results confirmed that the DOX and siRNA uptake efficiencies of PDA-DOX@SCM NPs were 96.2% and 91.5%, respectively, significantly higher than those of the PDA-DOX NPs group (75.5%) and the PDA-siRNA NPs group (69.3%). In the mouse model of prostate cancer bone metastasis, PDA-DOX@SCM NPs exhibited the slowest tumor volume growth, demonstrating significantly superior inhibitory effects compared to other groups (the PBS group, free DOX group, and PDA-DOX group, etc).134 In various solid tumors, including breast and ovarian cancers, macrophages, as integral components of the innate immune system, play pivotal roles in the phagocytosis and elimination of tumor cells during antitumor immune responses.135 Nevertheless, their antitumor efficacy is frequently hindered by two primary mechanisms: firstly, the low immunogenicity of breast cancer cells results in inadequate antigen presentation, thereby impeding the activation of macrophage immune recognition; secondly, breast cancer cells often overexpress the CD47 molecule, which conveys a “don’t eat me” signal to macrophages through the CD47/signal regulatory protein α (SIRP-α) signaling axis, thus creating an immune escape barrier.110 The traditional chemotherapy drug DOX is capable of inducing ICD to enhance antigen presentation, but its ability to modulate the CD47/SIRP-α axis is considerably constrained. Conversely, CD47 siRNA can selectively silence CD47 expression in tumor cells, thereby alleviating macrophage suppression. The combination of CD47 siRNA with DOX significantly enhances the antitumor efficacy mediated by macrophages. Nevertheless, the systemic administration of DOX and siRNA encounters several obstacles, including degradation by nucleases, clearance by the reticuloendothelial system, and inadequate tumor penetration.51 To address this issue, Song et al136 developed a co-delivery system utilizing pH-sensitive core-shell dendrimers (CSTDs). The core component incorporated β-cyclodextrin-modified fifth-generation (G5) poly(amidoamine) (PAMAM) dendrimers, which effectively loaded DOX through π–π stacking interactions. The shell was composed of benzimidazole-modified third-generation (G3) PAMAM, which employed electrostatic interactions to load CD47 siRNA, thereby facilitating the precise co-loading of hydrophobic and hydrophilic drugs. This system not only could promote the exposure of calreticulin on the tumor cell surface via DOX-induced ICD, thereby upregulating the “eat me” signal to enhance macrophage phagocytosis, but also could downregulate the “don’t eat me” signal by silencing CD47 gene expression through siRNA, thus alleviating macrophage phagocytic inhibition. Simultaneously, siRNA indirectly facilitated DC maturation and antigen presentation, ultimately activating T cell-mediated immune responses. The integration of this system with anti-CTLA-4 antibody-mediated ICB significantly attenuated T cell inhibitory signals, thereby establishing a cascading immune activation pathway. This pathway was centered on macrophages, facilitated by DCs, and culminated in the activation of T cell effector functions. Experimental results indicated that treatment of 4T1 cells with the G5@G3/CD47 siRNA complex resulted in a reduction of approximately 70% in CD47 mRNA expression levels compared to the PBS control group. In the 4T1 tumor-bearing mouse model, the treatment group receiving the G5@G3/DOX/CD47 siRNA complex combined with anti-CTLA-4 antibody exhibited the highest infiltration rates of CD8⁺ T cells and CD4⁺ T cells in tumor tissues, demonstrating the most potent tumor growth inhibition.136 Current nanocarriers often cannot precisely regulate the ratios of multiple drugs during loading and delivery processes, leading to suboptimal synergistic effects and unpredictable antitumor efficacy in combination therapies.46 In response to these challenges, Aryal et al137 introduced an innovative strategy involving drug-polymer covalent coupling. By covalently conjugating drugs to polymer chains of uniform length and structure, this strategy facilitates the controlled loading of multiple agents at defined ratios. This method is adaptable to various drug types and paves the way for the rapid assembly of NPs with precisely controlled multi-drug ratios. PTX, a well-established inducer of ICD, augments immune responses by facilitating the release of tumor antigens.138 Nevertheless, its hydrophobicity and associated systemic toxicity substantially constrain its therapeutic efficacy. Conversely, siRNA targeting the immune checkpoint protein PD-L1 (siPD-L1) can inhibit immune checkpoint pathways, modulate the production of inflammatory cytokines, and alter the TME to a more favorable state.139 The concomitant use of PTX and siPD-L1 has been shown to synergistically enhance systemic antitumor immunity. However, traditional nanomedicine systems have faced substantial challenges in achieving the precise co-delivery and targeted release of drugs with disparate physicochemical properties. To address this issue, Meng et al140 developed an immunoreactive polymer carrier, the polyethyleneimine-cholic acid conjugate (2E′). This carrier utilized a drug-polymer covalent coupling strategy, forming NPs (2E’/PTX/siPD-L1) through amphiphilic self-assembly. The hydrophobic core of cholic acid encapsulated PTX, while the cationic polyethyleneimine shell complexed with the negatively charged siPD-L1. This molecular engineering approach facilitated controllable dual-drug loading ratios (2E′:PTX:siPD-L1=1:0.2:0.67, wt/wt/wt) and enabled targeted release. Specifically, the 2E′ vector directly activated antigen-presenting cells, thereby promoting tumor antigen phagocytosis and presentation while enhancing T cell infiltration. PTX could induce tumor cell ICD, exposing calreticulin and releasing tumor antigens.138 siPD-L1 could effectively silence PD-L1 expression in tumor cells, blocking immune checkpoints and suppressing the recruitment of immunosuppressive cells (MDSCs, Tregs), thereby maintaining an immunologically active microenvironment. Experimental findings demonstrated that a single intratumoral administration of 2E′/PTX/siPD-L1 achieved a 25% complete response rate in primary tumors in the CT26 colon cancer mouse model. In the untreated side of the bilateral B16F10 model, tumor growth inhibition reached 71%. In metastatic 4T1 breast cancer models, the 2E’/PTX/siPD-L1 treatment group achieved an 88% inhibition rate of lung metastasis.140 Chemotherapy Drug - Cytokine Nanomedicine Systems As endogenous signaling proteins, cytokines play direct roles in the immunological reprogramming of the TME.141 Cytokine-based immunotherapies have the potential to enhance tumor cell sensitivity to chemotherapeutic agents while mitigating chemotherapy-induced resistance. Their precise synergistic interactions with chemotherapy drugs represent a promising strategy for enhancing antitumor efficacy. Nonetheless, substantial disparities exist between chemotherapy drugs and cytokines in terms of their physicochemical properties and pharmacokinetic profiles. Consequently, the development of combined delivery systems is essential to optimize therapeutic efficacy and minimize adverse effects (Table 3). Table 3Composition, Characteristics and Immune Activation Mechanisms of Nanomedicine Systems Co-Loaded with Chemotherapy Drugs and CytokinesChemotherapy DrugsCytokineNanocarrierCo-Loading SystemCharacteristicsImmune Activation PathwayKey Immune Cells InvolvedReferencesPaclitaxel (PTX)Interleukin-12 (IL-12)pH/thermo-dual responsive polymeric nanoparticles (mPEG-Dlinkm-PDLLA core/Pluronic F127 shell)Paclitaxel and IL-12 co-loaded thermo-sponge pH-sensitive nanoparticles (PTX/IL-12@TSNPpH)1. Acid-labile Dlinkm linker enables pH-responsive drug release in acidic TME.2. Low-temperature expansion of F127 shell achieves mild IL-12 encapsulation with preserved bioactivity.3. Enriches in breast tumors via EPR effect, suppresses tumor growth and lung metastasis, and prolongs overall survival.Low-dose PTX induces immunogenic cell death to release tumor antigens and promote DC maturation; IL-12 activates NK cells, drives Th1 polarization and IFN-γ secretion, and reprograms TAMs toward the M1 phenotype; combined treatment reduces Treg infiltration and amplifies CD8+ CTL-mediated antitumor immunity.Mature dendritic cells, CD4+ Th1 cells, CD8+ cytotoxic T cells, NK cells, M1-type tumor-associated macrophages; regulatory T cells, M2-type TAMs[142]PTXInterleukin-2 (IL-2)PLGA/Pluronic F127/mPEG-PLGA thermosponge nanoparticles (TSNs)PTX loaded in the hydrophobic core; IL-2 post-entrapped in the temperature-responsive shell (PTX/IL-2-TSNs)1. Solvent-free, mild post-entrapment preserved IL-2 bioactivity.2. Temperature-responsive swelling/deswelling enabled protein loading and sustained delivery.3. Inhibited tumor growth and metastasis and prolonged survival.Low-dose PTX enhanced tumor immunogenicity and disrupted the immunosuppressive tumor microenvironment; IL-2 promoted antitumor responses of immune effector cells. The original study also described PTX-mediated immunogenic cell death, regulatory T-cell depletion and dendritic-cell stimulation as contributing mechanisms.Cytotoxic T lymphocytes, NK cells and dendritic cells; regulatory T cells as an immunosuppressive target.[143]Doxorubicin (DOX)IL-12Chitosan/poly(L-glutamic acid) self-assembled nanoparticlesDOX/IL-12 co-loaded therapeutic nanoparticles (TNPs)1. Self-assembled via ionic interactions without additional stabilizers, with excellent biocompatibility and hemocompatibility.2. Prolongs blood circulation half-life and enhances tumor accumulation and cellular uptake.3. Acidic TME-responsive drug release, significantly inhibits H22 hepatoma growth with negligible systemic toxicity.DOX exerts direct cytotoxicity and induces tumor cell apoptosis; IL-12 released in situ repolarizes immunosuppressive M2-phenotype TAMs to tumoricidal M1 phenotype at a low dosage, reducing tumor burden and enhancing antitumor immune responses.M1-type tumor-associated macrophages, CD8+ cytotoxic T cells; M2-type tumor-associated macrophages[144]DOXRecombinant human interleukin-2 (rhIL-2)N,N,N-trimethyl chitosan (TMC)-based cationic nanocomplexesDOX covalently conjugated to TMC through cis-aconitic anhydride; rhIL-2 loaded by electrostatic adsorption (FTCD/rhIL-2)1. pH-sensitive DOX release and sustained rhIL-2 release.2. Preserved rhIL-2 bioactivity and protected it from enzymatic degradation.3. Delayed tumor growth with reduced toxicity; folate modification did not improve efficacy and was associated with weaker tumor inhibition.The nanocomplex combined DOX-mediated tumor-cell killing with rhIL-2-mediated immune stimulation. Compared with free drugs, it increased serum IgG and the abundance of tumor-infiltrating cytotoxic T lymphocytes.Tumor-infiltrating cytotoxic T lymphocytes; humoral immune response reflected by serum IgG.[145]Gemcitabine elaidatePlasmid interleukin-12 (pIL-12)CAF-targeted lipid-polymer hybrid nanoparticlespIL-12-loaded polymeric core combined with a JQ1/gemcitabine-elaidate co-loaded liposomal shell (PI/JGC/L-A)1. Converted the CAF barrier into a therapeutic drug depot.2. Normalized the CAF barrier and enhanced deep-tumor drug delivery through gemcitabine-loaded exosomes.3. Alleviated the immunosuppressive microenvironment and produced significant antitumor effects in PDAC.JQ1 normalized the CAF barrier, while CAF-derived exosomes transported gemcitabine to the deep tumor. Expression of pIL-12 enabled the engineered CAF depot to secrete IL-12, increase immune-cell infiltration and activate local antitumor immunity.CAF[146]Tirapazamine (TPZ)Interferon-γ (IFN-γ)Dual pH/ROS-responsive hydroxylated G3 PAMAM dendrimer nanogelsTPZ physically loaded within dendrimer nanogels; IFN-γ complexed on the nanogel surface (DNGs-TPZ/IFN-γ)1. Small and uniform nanogels (72.5 nm) with good colloidal stability.2. Tumor-microenvironment-triggered release and blood-brain-barrier penetration.3. Potent efficacy in an orthotopic glioma model.TPZ generated cytotoxic radicals under hypoxia, while IFN-γ upregulated pro-apoptotic signaling. Released IFN-γ promoted macrophage M1 polarization, dendritic-cell maturation and T-lymphocyte activation, while suppressing regulatory T cells.M1 macrophages, dendritic cells, T lymphocytes and regulatory T cells.[147]DOXIL-2 and IFN-γDrug-loaded nanovesiclesIL-2 adsorbed into DOX-loaded nanovesicles by a solvent-free method; IFN-γ subsequently introduced as a cytokine cocktail1. High cytokine encapsulation efficiency using a facile solvent-free method.2. Tumor accumulation and melanoma suppression with negligible systemic toxicity.3. Cytokine-cocktail nanovesicles inhibited primary tumor growth and lung metastasis in triple-negative breast cancer.The cytokine-cocktail nanovesicles facilitated dendritic-cell maturation, promoted infiltration and activation of CD8+ T lymphocytes and NK cells, and increased recruitment of CD45+ immune cells and Ly6G+ neutrophils.Dendritic cells, CD8+ T lymphocytes, NK cells, CD45+ immune cells and Ly6G+ neutrophils.[148]DOXIL-2 and IFN-γPELG-PEG-PELG thermosensitive polypeptide hydrogelLocalized DOX/IL-2/IFN-γ co-loaded injectable hydrogel depot1. Initial burst release during the first 3 days followed by sustained release for 26 days.2. Complete degradation within 3 weeks with good biocompatibility.3. Enhanced tumor inhibition without obvious systemic toxicity.The combination increased tumor-cell apoptosis, reduced Bcl-2, increased caspase-3 and enhanced G2/S-phase arrest. Sustained cytokine delivery promoted proliferation of CD3+/CD4+ and CD3+/CD8+ T lymphocytes.CD3+/CD4+ T lymphocytes and CD3+/CD8+ T lymphocytes.[149]Abbreviations: CAF, cancer-associated fibroblast; CTL, cytotoxic T lymphocyte; DCs, dendritic cells; DOX, doxorubicin; EPR, enhanced permeability and retention effect; F127, Pluronic F127; IFN-γ, interferon-γ; IgG, immunoglobulin G; IL-2, interleukin-2; IL-12, interleukin-12; mPEG, methoxy polyethylene glycol; NK, natural killer; PAMAM, poly(amidoamine); PDAC, pancreatic ductal adenocarcinoma; PDLLA, poly(D,L-lactic acid); PEG, polyethylene glycol; PELG, poly(ethyl-L-glutamate); pIL-12, plasmid interleukin-12; PLGA, poly(lactic acid-co-glycolic acid); PTX, paclitaxel; rhIL-2, recombinant human interleukin-2; ROS, reactive oxygen species; TAMs, tumor-associated macrophages; Th1, T helper 1; TMC, N,N,N-trimethyl chitosan; TME, tumor microenvironment; TNPs, therapeutic nanoparticles; TPZ, tirapazamine; Tregs, regulatory T cells; TSNs, thermosponge nanoparticles. Composition, Characteristics and Immune Activation Mechanisms of Nanomedicine Systems Co-Loaded with Chemotherapy Drugs and Cytokines Abbreviations: CAF, cancer-associated fibroblast; CTL, cytotoxic T lymphocyte; DCs, dendritic cells; DOX, doxorubicin; EPR, enhanced permeability and retention effect; F127, Pluronic F127; IFN-γ, interferon-γ; IgG, immunoglobulin G; IL-2, interleukin-2; IL-12, interleukin-12; mPEG, methoxy polyethylene glycol; NK, natural killer; PAMAM, poly(amidoamine); PDAC, pancreatic ductal adenocarcinoma; PDLLA, poly(D,L-lactic acid); PEG, polyethylene glycol; PELG, poly(ethyl-L-glutamate); pIL-12, plasmid interleukin-12; PLGA, poly(lactic acid-co-glycolic acid); PTX, paclitaxel; rhIL-2, recombinant human interleukin-2; ROS, reactive oxygen species; TAMs, tumor-associated macrophages; Th1, T helper 1; TMC, N,N,N-trimethyl chitosan; TME, tumor microenvironment; TNPs, therapeutic nanoparticles; TPZ, tirapazamine; Tregs, regulatory T cells; TSNs, thermosponge nanoparticles. As previously mentioned, PTX exerts antitumor effects not only through direct cytotoxicity but also by inducing ICD, thereby promoting the release of tumor-associated antigens.128 Concurrently, IL-12, a hydrophilic macromolecular cytokine, can modulate the TME by regulating the expression of surface receptors on DCs and natural killer (NK) cells, thereby activating NK cells and T cells.117,129 Research has demonstrated that the combination of IL-12 and PTX yields synergistic antitumor effects. PTX facilitates tumor antigen release through ICD, whereas IL-12-based immunotherapy enhances tumor sensitivity to chemotherapy, mitigates chemotherapy-associated adverse effects, and counteracts therapeutic resistance.130 Nonetheless, the clinical application of IL-12 remains limited by severe adverse effects, including systemic inflammatory response syndrome and hepatotoxicity, largely attributable to elevated systemic exposure. Additionally, significant disparities exist between IL-12 and PTX in terms of their physicochemical properties and pharmacokinetics. Hu et al142 developed a nanomedicine system based on a polylactic acid copolymer (mPEG-Dlinkm-PDLLA) in conjunction with Pluronic F127 (F127). Hydrophobic PTX was incorporated via nanoprecipitation, whereas IL-12 was encapsulated through a low-temperature expansion effect enabled by the thermosensitivity of F127. This strategy successfully achieved stable co-loading of both agents while significantly reducing systemic IL-12 exposure, thereby mitigating cytokine storm-associated toxicity. The nanomedicine system demonstrated EPR-mediated accumulation at breast tumor sites and facilitated Dlinkm bond cleavage within the acidic TME. This subsequently released PTX, which directly killed tumor cells and induced ICD, thereby promoting tumor antigen release. Simultaneously, IL-12 promoted local T cell activation, induced TAM polarization toward the M1 phenotype, and initiated antitumor immune responses. Experimental results indicated that the combination therapy group achieved a tumor inhibition rate of 84.3% and significantly prolonged the survival of tumor-bearing mice, demonstrating markedly superior efficacy compared with both PTX and IL-12 monotherapy groups.142 Glioma is characterized by profound hypoxia and an immunosuppressive tumor microenvironment, while the blood–brain barrier (BBB) further restricts the effective delivery of chemotherapeutic agents and cytokines.150 Tirapazamine (TPZ) generates cytotoxic radicals and induces DNA damage under hypoxic conditions, but its therapeutic efficacy is limited by poor BBB penetration.151,152 IFN-γ can activate STAT1- and caspase-associated apoptotic pathways while promoting M1 macrophage polarization, DC maturation, and T-cell activation.153 Nevertheless, free IFN-γ has a short circulatory half-life and a narrow therapeutic window. Integrating hypoxia-selective TPZ chemotherapy with IFN-γ-mediated immune regulation within a BBB-penetrating carrier may therefore provide mechanistically complementary chemoimmunotherapy for glioma. Wang et al147 developed dual pH/ROS-responsive dendrimer nanogels based on hydroxylated generation-3 poly(amidoamine) dendrimers for the co-delivery of TPZ and IFN-γ (DNGs-TPZ/IFN-γ). TPZ was physically encapsulated within the nanogel network, whereas IFN-γ was complexed on the surface through ionic and cation-π interactions. The resulting nanogels had a mean diameter of approximately 72.5 nm and could cross the BBB through their hydroxyl-rich surface and the enhanced permeability and retention effect, followed by release of both therapeutic components within the tumor microenvironment. In vitro, under hypoxic conditions and at a TPZ-equivalent concentration of 50 μg/mL, DNGs-TPZ/IFN-γ reduced C6 cell viability to approximately 36%, compared with approximately 58% and 62% for free TPZ and DNGs-TPZ, respectively. The formulation also produced an M1/M2 macrophage ratio of 10.44% and a mature DC proportion of 11.0%, accompanied by pronounced activation of the STAT1/caspase-8/caspase-3 apoptotic pathway. In an orthotopic glioma model, DNGs-TPZ/IFN-γ reduced the final relative tumor volume by approximately 83% compared with PBS and by approximately 66% compared with DNGs-TPZ alone (approximately 3.2 vs 19.0 and 9.5, respectively). At 20 days after treatment, the survival rate reached 80%, compared with 40% for DNGs-TPZ and less than 20% for free TPZ. The formulation also produced the highest tumor-cell apoptosis rate and the lowest Ki67-positive fraction, at 11.65% and 8.39%, respectively. Immune profiling further showed that the proportions of splenic CD4⁺ and CD8⁺ T cells increased to 16.3% and 52.3%, respectively, accompanied by reduced CD206+ TAMs and increased CD11c+ DCs within the tumor. These findings demonstrate that the nanogel enhanced BBB penetration and integrated hypoxia-activated TPZ chemotherapy with IFN-γ-mediated remodeling of the immune microenvironment, thereby improving therapeutic efficacy against orthotopic glioma.147 Chemotherapy Drug - TCM Nanomedicine Systems Recently, both in vitro and in vivo studies have demonstrated that integrating antitumor bioactive constituents derived from TCM with chemotherapy drugs can produce synergistic effects through multitarget mechanisms. This strategy can not only enhance the sensitivity of tumor cells to chemotherapy but also modulate the TME, thereby activating immune cell-mediated cytotoxicity against tumor cells while concurrently suppressing the development of drug resistance.154 Nonetheless, traditional co-delivery strategies present several challenges in the simultaneous administration of chemotherapy drugs and TCM-derived active compounds. Specifically, chemotherapy drugs are typically characterized by rapid absorption and distribution, whereas TCM-derived active compounds often exhibit slower absorption because of their complex structures and physicochemical properties. This discrepancy in absorption kinetics hinders the simultaneous accumulation of both agents at tumor sites, thereby limiting their potential synergistic efficacy.51 Additionally, intrinsic differences in their chemical structures may cause interactions that adversely affect solubility and stability or even induce the formation of new compounds, thereby increasing the risk of drug incompatibility.155 Collectively, these factors compromise the safety and therapeutic efficacy of the regimen.156 Nanomedicine systems offer a promising strategy for achieving the synergistic delivery and controlled release of these two classes of active agents (Table 4). Table 4Composition, Characteristics and Immune Activation Mechanisms of Nanomedicine Systems Co-Loaded with Chemotherapy Drugs and TCMChemotherapy DrugsTCMNanocarrierCo-Loading SystemCharacteristicsImmune Activation PathwayKey Immune Cells InvolvedReferencesDoxorubicin (DOX)Ginsenoside Rg3(Rg3)LiposomeA biomimetic nanomedicine system (DR@PLip) based on Pm coating and DOX/Rg3 co-loading1. Synergistically enhanced the anti-arrhythmic effect of ICD.2. Targeted deep lesions to suppress recurrence and established immune memory.DOX induces ICD of leukemia cells with CRT exposure and HMGB1/ATP release; ginsenoside Rg3 enhances intracellular ROS production to amplify the ICD effect, promoting dendritic cell maturation and T-cell activation. Combined with anti-PD-L1, it further boosts effector T cell infiltration into the bone marrow and induces long-term immune memory.Dendritic cells, CD4+ T cells, CD8+ cytotoxic T cells, effector memory T cells[157]DOXQUEHA-modified zeolite imidazole framework (ZIF) (HA/ZIF)QUE and DOX co-loaded HA/ZIF (HA/ZIF/DQ)1. Synergistic chemotherapy with TME modulation enhanced deep tumor penetration.2. Dual mechanism of “active targeting + pH-responsive release” boosted antitumor efficacy while reducing systemic toxicity.Quercetin reduces stromal collagen and α-SMA expression to break down the tumor physical barrier, remodel the microenvironment and promote deep drug penetration, enhancing chemotherapeutic efficacy.Tumor-associated fibroblasts (main target of stromal remodeling); no specific immune cell subsets were investigated in this study.[158]DOXQuercetin (QUE)The polymer dextran-phenylboronic acidquercetin (DEX-PBA-QUE)DOX encapsulated in DEX-PBA-QUE NPs (DPQ-DOX NPs)1. pH/ROS dual-response drug released.2. Synergistic immune modulation for potent antitumor activity.DOX induces tumor ICD to release DAMPs and initiate the immune cascade; quercetin inhibits the COX2-PGE2 axis to reverse the immunosuppressive microenvironment, synergistically amplifying antitumor immunity.Dendritic cells, CD4+ T cells, CD8+ cytotoxic T cells, NK cells, M1-type macrophages; Tregs, MDSCs, M2-type macrophages[159]DOXAngelica sinensis polysaccharide (AP)Carrier-free nanomedicine systemsAngelica sinensis polysaccharide-peptide-DOX NPs (AP-PP-DOX)1. Enzyme-responsive synergistic therapy.2. Dual-function carrier design.Released Angelica sinensis polysaccharide acts as an immunoadjuvant, upregulates the Th1 cytokine IL-2 and downregulates the Th2 cytokine IL-10, restoring the Th1/Th2 immune balance in the tumor microenvironment.CD4+ T helper cells, CD8+ T cells, dendritic cells, macrophages[160]DOXIngenol-3-angelate (I3A)PLA-PEG-ACUPA/TPP polymeric nanoparticles (NPs)I3A/DOX NP-A/T (PSMA & mitochondria cascade-targeted NPs)I3A/DOX NP-A/T (PSMA & mitochondria cascade-targeted NPs)I3A triggers mitophagy to boost ATP release and synergizes with DOX to amplify immunogenic cell death (CRT exposure, HMGB1 and ATP secretion); I3A also inhibits VEGF to normalize tumor vasculature and promote immune cell infiltration; released DAMPs drive DC maturation and adaptive antitumor immunity.Dendritic cells, CD4⁺ T cells, CD8⁺ cytotoxic T cells; vascular endothelial cells (target of vascular normalization)[161]DOXBerberine (BER)NPsDOX/BER co-loaded NPs1. Downregulates tumor PD-L1 and eliminates cancer stem cells in triple-negative breast cancer.2. Exerts synergistic chemo-immunotherapy and reduces tumor recurrenceDOX triggers immunogenic cell death to release tumor antigens; berberine downregulates PD-L1 to reverse immune checkpoint suppression and amplify antitumor immunity.Dendritic cells, CD8+ cytotoxic T cells; cancer stem cells (targeted depletion)[162]Oxaliplatin (L-OHP)Curcumin (CUR)Hydroxyapatite (HAP) nanovehicleCurcumin/L-OHP co-loaded HAP NPs (Cur/L-OHP@HAP)1. pH-responsive degradation in acidic TME.2. High drug loading at a fixed molar ratio.3Targeted activation of innate immune pathway in colorectal cancer.Oxaliplatin induces DNA damage and releases cytoplasmic dsDNA; curcumin synergistically activates the cGAS-STING innate immune pathway to promote T cell infiltration and amplify antitumor immunity.CD8+ cytotoxic T cells, dendritic cells (cGAS-STING pathway activation)[163]Docetaxel (DTX)CURCarboxymethyl chitosan CMCS-4-hydroxybenzeneboronic acid pinacol ester (BAPE) nanomicelleNovel T7 peptide-modified NPs co-loaded with DTX and CUR (CBT-DC)1. T7 peptide enabled specific recognition and precise targeting, with dual pH/ROS-responsive drug release.2. Synergistic antitumor effects and reshaping of the immune microenvironment.Docetaxel exerts direct cytotoxic effects; curcumin ameliorates the immunosuppressive microenvironment by downregulating the immunosuppressive cytokine IL-10 and reducing immunosuppressive cell infiltration.NK cells, M1-type macrophages; MDSCs, regulatory T cells[164]Low-molecular-weight heparin (LMWH)CURCarrier-free nanomedicine systemsNanomedicine system co-loading LMWH and CUR (LCU)1. Synergistically enhanced anti-angiogenic effects with direct anti-tumor activity.2. Improved targeting and stability to achieve low-dose, high-efficacy treatment.Low molecular weight heparin sequesters pro-angiogenic factors (VEGF, bFGF); curcumin suppresses angiogenic signaling. The two synergistically inhibit tumor angiogenesis and cut off tumor nutrient supply.Vascular endothelial cells (main therapeutic target); no specific immune cell subsets were investigated in this study.[165]Cisplatin (CDDP)Rg3Ginsenoside Rg3-integrated liposomeCisplatin/ICG co-loaded Rg3-based liposomes (RID-LPs)1. Rg3 acts as a membrane component to reverse multidrug resistance.2. Triple synergy of chemotherapy, photothermal therapy and immunotherapy.3. Prolonged circulation and enhanced tumor accumulation.Combined photothermal effect and cisplatin induce tumor pyroptosis and release DAMPs; Rg3 remodels the immunosuppressive tumor microenvironment; they jointly promote DC maturation and boost T cell-mediated antitumor immunity.Dendritic cells, CD8⁺ cytotoxic T cells, M1-phenotype tumor-associated macrophages[166]PTXRg3LiposomePaclitaxel-loaded ginsenoside Rg3 liposomesAchieved dual targeting of tumor cells and the TME, reversing multidrug resistance (MDR).Inhibits the IL-6/STAT3/p-STAT3 signaling pathway to remodel the immunosuppressive tumor microenvironment; paclitaxel exerts direct cytotoxicity and ginsenoside Rg3 reverses multidrug resistance.M1-type tumor-associated macrophages; M2-type tumor-associated macrophages, MDSCs[167]Abbreviations: AP, Angelica sinensis polysaccharide; ATP, adenosine triphosphate; BAPE, 4-hydroxybenzeneboronic acid pinacol ester; BER, berberine; bFGF, basic fibroblast growth factor; CDDP, cisplatin; cGAS, cyclic GMP–AMP synthase; CMCS, carboxymethyl chitosan; COX-2, cyclooxygenase-2; CRT, calreticulin; CUR, curcumin; DAMPs, damage-associated molecular patterns; DOX, doxorubicin; dsDNA, double-stranded DNA; DTX, docetaxel; HA, hyaluronic acid; HAP, hydroxyapatite; HMGB1, high mobility group box 1; I3A, ingenol-3-angelate; ICD, immunogenic cell death; ICG, indocyanine green; IL-2, interleukin-2; IL-6, interleukin-6; IL-10, interleukin-10; LMWH, low-molecular-weight heparin; L-OHP, oxaliplatin; MDR, multidrug resistance; MDSCs, myeloid-derived suppressor cells; NK, natural killer; NPs, nanoparticles; PBA, phenylboronic acid; PD-L1, programmed death-ligand 1; PEG, polyethylene glycol; PGE2, prostaglandin E2; PLA, poly(lactic acid); Pm, platelet membrane; PSMA, prostate-specific membrane antigen; PTX, paclitaxel; QUE, quercetin; Rg3, ginsenoside Rg3; ROS, reactive oxygen species; STING, stimulator of interferon genes; Th1, T helper 1; Th2, T helper 2; TME, tumor microenvironment; TPP, triphenylphosphonium; Tregs, regulatory T cells; VEGF, vascular endothelial growth factor; ZIF, zeolite imidazole framework; α-SMA, α-smooth muscle actin. Composition, Characteristics and Immune Activation Mechanisms of Nanomedicine Systems Co-Loaded with Chemotherapy Drugs and TCM Abbreviations: AP, Angelica sinensis polysaccharide; ATP, adenosine triphosphate; BAPE, 4-hydroxybenzeneboronic acid pinacol ester; BER, berberine; bFGF, basic fibroblast growth factor; CDDP, cisplatin; cGAS, cyclic GMP–AMP synthase; CMCS, carboxymethyl chitosan; COX-2, cyclooxygenase-2; CRT, calreticulin; CUR, curcumin; DAMPs, damage-associated molecular patterns; DOX, doxorubicin; dsDNA, double-stranded DNA; DTX, docetaxel; HA, hyaluronic acid; HAP, hydroxyapatite; HMGB1, high mobility group box 1; I3A, ingenol-3-angelate; ICD, immunogenic cell death; ICG, indocyanine green; IL-2, interleukin-2; IL-6, interleukin-6; IL-10, interleukin-10; LMWH, low-molecular-weight heparin; L-OHP, oxaliplatin; MDR, multidrug resistance; MDSCs, myeloid-derived suppressor cells; NK, natural killer; NPs, nanoparticles; PBA, phenylboronic acid; PD-L1, programmed death-ligand 1; PEG, polyethylene glycol; PGE2, prostaglandin E2; PLA, poly(lactic acid); Pm, platelet membrane; PSMA, prostate-specific membrane antigen; PTX, paclitaxel; QUE, quercetin; Rg3, ginsenoside Rg3; ROS, reactive oxygen species; STING, stimulator of interferon genes; Th1, T helper 1; Th2, T helper 2; TME, tumor microenvironment; TPP, triphenylphosphonium; Tregs, regulatory T cells; VEGF, vascular endothelial growth factor; ZIF, zeolite imidazole framework; α-SMA, α-smooth muscle actin. Acute myeloid leukemia (AML) is a hematologic malignancy characterized by uncontrolled proliferation and differentiation arrest of myeloid cells.168 The widespread distribution of leukemic lesions and intrinsic drug resistance in AML result in limited chemotherapeutic efficacy and high recurrence rates. Notably, ginsenoside Rg3, a bioactive compound extracted from the TCM herb Panax ginseng, has been shown to induce ICD in AML by stimulating ROS production.169 Moreover, ginsenoside Rg3 can enhance the sensitivity of tumor cells to chemotherapeutic agents, such as DOX, through multitarget regulatory mechanisms.170,171 Chen et al157 developed a PM-modified liposomal system (DR@PLip) for the co-delivery of DOX and Rg3. This system optimized the spatial distribution of both agents by exploiting the bilayer architecture of liposomes: hydrophobic ginsenoside Rg3 was incorporated into the lipid bilayer, whereas hydrophilic DOX hydrochloride was encapsulated within the aqueous core during lipid bilayer hydration. Furthermore, PM coating significantly prolonged the circulation time of DR@PLip and facilitated targeted accumulation through the specific interaction between P-selectin (CD62p) and CD44 on the surface of AML cells. Experimental results demonstrated that DR@PLip sustained the release of ginsenoside Rg3 over 25 hours, thereby enabling prolonged antitumor immune activation. Concurrently, the controlled release of DOX prolonged the preservation of its cytotoxic activity. The synergistic interaction of ginsenoside Rg3 and DOX significantly enhanced the immune antitumor effect, as evidenced by an increase in calreticulin exposure to 58.5%, along with elevated levels of high mobility group box 1 (HMGB1) release and ATP secretion compared to other experimental groups. DR@PLip promoted DC maturation to 56% and enhanced CD8+ T cell-mediated immune surveillance, thereby achieving synergistic chemo-immunotherapeutic effects and improving long-term survival outcomes in AML.157 In recent years, PCa has become one of the most prevalent malignancies among men worldwide.172 The efficacy of traditional chemotherapeutic agents, such as DOX, is often limited by the immunosuppressive characteristics of the TME, frequently resulting in tumor recurrence.173 Ingenol-3-angelate (I3A), a diterpenoid compound derived from the TCM herb Euphorbia peplus, significantly enhances DOX-induced ICD by promoting mitochondrial autophagy and apoptotic pathways,174 while also remodeling tumor vasculature through inhibition of vascular endothelial growth factor expression.175 Nonetheless, the combined use of I3A and DOX presents several challenges, including the pronounced hydrophobicity and acute toxicity associated with both compounds. Wang et al161 developed PLA-PEG nanoparticles (I3A/DOX NP-A/T) co-modified with the PSMA-targeting ligand ACUPA and the mitochondria-targeting moiety triphenylphosphonium (TPP). The surface modification with ACUPA enabled specific recognition of the PSMA receptor, which was highly expressed in prostate cancer, thereby facilitating the accumulation of NPs in tumor tissues. The incorporation of TPP enabled precise subcellular mitochondrial targeting. This system co-encapsulated I3A and DOX in a 1:4 molar ratio within the NP core via hydrophobic interactions and π-π stacking effects. Furthermore, it leveraged pH-responsive release properties to achieve synergistic delivery within the acidic lysosomal environment, thereby ensuring the targeted release of both agents at an optimal ratio. I3A-mediated vascular normalization significantly reduced tumor interstitial pressure, enhanced CD8+ T cell infiltration, and markedly upregulated key immune mediators, including IFN-γ and TNF-α, thereby effectively reversing the immunosuppressive microenvironment. In vivo results in the RM-1 xenograft mouse model showed that the I3A/DOX NP-A/T group achieved an estimated tumor growth inhibition rate of approximately 72% on day 18 post-treatment, which was markedly superior to all monotherapy nanoparticle groups. The dual-targeted co-delivery group also exhibited significantly prolonged overall survival, with no obvious body weight loss or histopathological damage to major organs. Immunological analysis revealed substantially increased proportions of mature dendritic cells, CD4+ T cells and CD8+ T cells in tumor tissues, along with significantly upregulated levels of IFN-γ, TNF-α and IL-12, indicating robust antitumor immune activation.161 Triple-Component Nanomedicine Systems Compared with dual-component nanomedicine systems, triple-component nanomedicine systems offer greater therapeutic advantages. However, these systems also impose greater demands on the integrated design of targeted delivery, spatiotemporal controllability, and synergistic therapeutic strategies. These systems are characterized by increased structural complexity and pose greater design challenges. By incorporating multiple functional components, such as highly specific targeting ligands, stimuli-responsive carriers, and auxiliary functional elements, triple-component systems can not only overcome the payload limitations inherent to conventional drug delivery systems but also enable more precise and efficient drug delivery and release through multilevel regulatory mechanisms. Moreover, this synergistic multicomponent design provides innovative technical strategies for overcoming tumor heterogeneity and multidrug resistance (Table 5). Table 5Composition, Characteristics, and Immune Activation Mechanisms of Triple-Component Nanomedicine SystemsTherapeutic ComponentsRoles of the Three ComponentsNanocarrierCo-loading SystemCharacteristicsImmune Activation PathwayKey Immune Cells InvolvedReferencesGemcitabine (GEM)anti-PD-L1 antibody (αPD-L1)Diamidobenzimidazole STING agonist (diABZI)-3GEM: Induces tumor-cell apoptosis and antigen exposure.αPD-L1: Blocks PD-1/PD-L1-mediated immunosuppression and counteracts GEM-associated PD-L1 upregulation.diABZI-3: Activates STING signaling and promotes dendritic-cell maturation.PLA-GEM macromolecular prodrug formulated with PEG-PLA and maleimide-functionalized PEG-PLATriple therapy-integrated GPS nanovesicles: diABZI-3 encapsulated in GEM prodrug nanoparticles and αPD-L1 covalently conjugated to the surface1. Integrated chemotherapy, immune-checkpoint blockade, and STING activation in one scaffold.2. αPD-L1 decoration enhanced cellular uptake and intratumoral delivery; nanodelivery improved the pharmacokinetic behavior of GEM and diABZI-3.3. Converted poorly immunogenic tumors into inflamed tumors and supported recurrence-free antitumor responses in preclinical models.GEM induced tumor-cell apoptosis and antigen exposure. Encapsulated diABZI-3 activated STING-associated signaling and increased IFN-β and IL-6 expression, promoting dendritic-cell maturation and inflammatory conversion of the TME. αPD-L1 blocked PD-1/PD-L1-mediated suppression and amplified CD8+ T-cell responses. The system also promoted migration of CD103+ dendritic cells from tumors to tumor-draining lymph nodes.Dendritic cells, including CD103+ dendritic cells; CD8+ T cells; macrophages were also evaluated as STING-responsive cells.[176]Lanthanum ions (La3+)2’3’-cyclic GMP-AMP (cGAMP)PTPN6 siRNA (siPTPN6)cGAMP: Activates STING signaling.La3+: Enhances STING phosphorylation and downstream signal transduction.siPTPN6: Suppresses SHP-1 and thereby increases K63-linked ubiquitination of STING.Lanthanum phosphate core containing cGAMP and siPTPN6, coated with aminopropylimidazole- and alendronate-modified hyaluronic acid (IAHA)Three-in-one IAHA-LaP/siPTPN6 nanoparticles for triple amplification of dendritic-cell STING signaling1. Combined direct STING agonism, lanthanum-mediated signal potentiation, and suppression of the SHP-1 negative regulator.2. Increased IFN-β, IL-6, and TNF-α secretion and promoted systemic antitumor immunity.3. Suppressed primary and distal B16F10 tumors and generated long-term immune memory against recurrence.cGAMP initiated STING signaling. La3+ enhanced phosphorylation of STING, TBK1, IRF3, and NF-κB p65. siPTPN6 downregulated SHP-1, further enhanced STING/NF-κB phosphorylation, and increased K63-linked ubiquitination of STING. These effects promoted dendritic-cell maturation, M2-to-M1 macrophage polarization, and intratumoral CD8+ T-cell infiltration.Mature dendritic cells, M1- and M2-phenotype macrophages, and CD8+ T cells.[177]2-(2-Nitroimidazol-1-yl) acetic acid radiosensitizer (NIA)PD-L1 antagonist peptide D-PPA-1Toll-like receptor 7/8 agonist resiquimod (R848)NIA: Acts as a hypoxia-targeted radiosensitizer and enhances radiotherapy-induced tumor-cell apoptosis.D-PPA-1: Antagonizes PD-L1 and relieves PD-1/PD-L1-mediated T-cell suppression.R848: Activates TLR7/8 and promotes dendritic-cell maturation.Matrix metalloproteinase-2-responsive amphiphilic peptide-drug conjugate co-assembled with R848NIA-D1@R848 three-in-one nanoparticles used in combination with radiotherapy1. Integrated hypoxic-tumor radiosensitization, PD-L1 antagonism, and innate immune adjuvancy.2. The peptide-drug conjugate contained an MMP-2 substrate sequence for tumor-associated responsiveness.3. Addressed both hypoxia-associated radioresistance and radiotherapy-induced PD-L1 upregulation.NIA enhanced radiotherapy-induced tumor-cell apoptosis under hypoxic conditions and facilitated initiation of the cancer-immunity cycle. R848 activated TLR7/8 and promoted dendritic-cell maturation. D-PPA-1 blocked PD-1/PD-L1 signaling, relieved T-cell suppression, and amplified the systemic antitumor immune response.Dendritic cells and T lymphocytes[178]Chlorin e6 (Ce6)Dextro-1-methyl tryptophan (1-MT)αPD-L1Ce6: Mediates photodynamic therapy to generate tumor antigens and initiate antigen presentation.1-MT: Inhibits the IDO pathway and supports lymphocyte activation and proliferation.αPD-L1: Blocks the PD-1/PD-L1 checkpoint during tumor-cell elimination.Ce6-conjugated hyaluronic acid and 1-MT-conjugated polylysine assembled into nanoparticles with surface-associated αPD-L1αPD-L1@HC/PM three-in-one immunotherapy nanoparticles1. Designed for stepwise detachment and delivery of three immunotherapeutic functions to their respective sites of action.2. Sequentially regulated antigen presentation, lymphocyte activation/proliferation, and tumor-cell elimination.3. Inhibited tumor metastasis, relapse, and postsurgical regrowth in preclinical models.Near-infrared irradiation of the Ce6-containing component generated tumor antigens and initiated antigen presentation. Released 1-MT inhibited the IDO immunosuppressive pathway to support lymphocyte activation. αPD-L1 blocked the PD-1/PD-L1 checkpoint during the tumor-elimination phase, producing cascade amplification of the cancer-immunity cycle.Antigen-presenting cells and T lymphocytes[179]Oxaliplatin prodrug (OX)Gemcitabine monophosphate/prodrug (GC)5-Carboxy-8-hydroxyquinoline (CQ)OX: Induces immunogenic cell death and tumor-antigen release.GC: Provides complementary chemotherapy and contributes to immunogenic cell death.CQ: Amplifies OX/GC-induced immunogenic cell death and downregulates tumor PD-L1.Zn2+-coordinated nanoscale coordination polymer with an OX/GC core and a cholesterol-CQ-containing lipid coatingpH-responsive OX/GC/CQ three-in-one nanoscale coordination polymer1. Co-delivered two chemotherapeutic prodrugs and an immunomodulatory quinoline derivative.2. Improved pharmacokinetics, tumor accumulation, and drug release in acidic tumor tissues.3. Suppressed colorectal carcinoma and triple-negative breast tumors, reduced lung metastasis, and prolonged survival.OX and GC induced immunogenic cell death, including CRT exposure and HMGB1/ATP release, which promoted dendritic-cell maturation. CQ enhanced OX/GC-induced immunogenic cell death and downregulated tumor PD-L1 expression, thereby disrupting PD-1/PD-L1 suppression, increasing cytotoxic T-lymphocyte infiltration/activity, and reducing regulatory T cells.Mature dendritic cells, CD8+ cytotoxic T lymphocytes, regulatory T cells, and tumor-infiltrating leukocytes.[180]Anti-CD47 antibodyαPD-L1Diamidobenzimidazole STING agonist diABZIAnti-CD47 antibody: Promotes myeloid-cell engagement, phagocytosis, and tumor-antigen presentation.αPD-L1: Blocks PD-L1-mediated immune-checkpoint suppression.diABZI: Activates STING/type I interferon signaling in tumor-associated myeloid cells.Dual-antibody-functionalized bridging lipid nanoparticle encapsulating diABZIdiABZI-loaded CD47/PD-L1-targeting bridging lipid nanoparticles (B-LNP/diABZI), combined with radiotherapy1. Dual ligation bridged tumor-associated myeloid cells to glioblastoma cells while blocking two immune checkpoints.2. Encapsulated diABZI reprogrammed immunosuppressive myeloid cells into antitumor effectors.3. Synergized with radiotherapy to promote tumor regression and immunological memory.Anti-CD47 and αPD-L1 ligation promoted myeloid-cell engagement, phagocytosis, and tumor-antigen presentation. Intracellular diABZI activated STING/type I interferon signaling in tumor-associated myeloid cells, inducing a transcriptomic and metabolic switch that supported T-cell recruitment and activation in brain tumors.Tumor-associated myeloid cells/macrophages and activated CD8+ T cells.[181]GEMPaclitaxel (PTX)CpG oligonucleotide (CpG)GEM: Provides cytotoxic chemotherapy and enhances tumor-cell apoptosis.PTX: Contributes to chemotherapy-induced immunogenic cell death.CpG: Acts as a nanoscale immune adjuvant and promotes dendritic-cell maturation.Integrin-targeting micellar GEM/PTX formulation (ATN-mG/P) used with polymersomal CpG (NanoCpG)Coordinated triple-component nano-combination: GEM and PTX co-delivered in ATN-mG/P, with CpG delivered in a separate polymersomal nanoadjuvant1. Combined dual-drug chemotherapy with a nanoscale immune adjuvant to convert postoperative “cold” TNBC into an immunologically active state.2. Increased tumor-cell apoptosis and immunogenicity.3. Completely inhibited lung metastasis and maintained 60% of treated mice tumor-free in the reported postoperative model.ATN-mG/P enhanced 4T1-cell apoptosis, induced immunogenic cell death, and stimulated bone-marrow-derived dendritic-cell maturation. NanoCpG provided immune adjuvancy. The combination increased mature dendritic cells and CD8+ T cells while reducing myeloid-derived suppressor cells and regulatory T cells.Mature dendritic cells, CD8+ T cells, myeloid-derived suppressor cells, and regulatory T cells.[70]Irinotecan (CPT-11)R848αPD-L1CPT-11: Induces immunogenic cell death with HMGB1 release and CRT exposure.R848: Activates TLR7, promotes dendritic-cell maturation, and stimulates inflammatory immune signaling.αPD-L1: Blocks PD-L1-mediated immune evasion and strengthens antitumor immunity.Hyaluronic-acid-coated MIL-100(Fe) metal-organic framework co-loading CPT-11 and R848Coordinated triple-component nano-combination: CPT-11/R848-loaded CRMH nanoparticles administered with αPD-L11. HA coating enabled CD44-mediated tumor targeting and acidic-TME-responsive release.2. Integrated chemotherapy, TLR7 agonism, and immune-checkpoint blockade.3. Enhanced local and distant-tumor control and was proposed to overcome immune evasion in colorectal cancer.CPT-11 induced immunogenic cell death with HMGB1 release and CRT exposure. R848 activated TLR7, promoted dendritic-cell maturation, and contributed to cGAS-STING activation, type I interferon production, inflammatory cytokine release, and T-cell recruitment. Because CRMH nanoparticles increased tumor PD-L1, combination with αPD-L1 further enhanced antitumor immunity.Dendritic cells and T cells[182]Abbreviations: 1-MT, dextro-1-methyl tryptophan; ATP, adenosine triphosphate; Ce6, chlorin e6; cGAMP, 2′3′-cyclic GMP–AMP; cGAS, cyclic GMP–AMP synthase; CpG, CpG oligonucleotide; CPT-11, irinotecan; CQ, 5-carboxy-8-hydroxyquinoline; CRT, calreticulin; diABZI, diamidobenzimidazole STING agonist; GC, gemcitabine monophosphate/prodrug; GEM, gemcitabine; HA, hyaluronic acid; HMGB1, high mobility group box 1; IAHA, aminopropylimidazole- and alendronate-modified hyaluronic acid; IDO, indoleamine 2,3-dioxygenase; IFN-β, interferon-β; IL-6, interleukin-6; IRF3, interferon regulatory factor 3; La3⁺, lanthanum ions; LaP, lanthanum phosphate; MMP-2, matrix metalloproteinase-2; NF-κB, nuclear factor kappa B; NIA, 2-(2-nitroimidazol-1-yl) acetic acid; OX, oxaliplatin prodrug; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PEG, polyethylene glycol; PLA, poly(lactic acid); PTX, paclitaxel; PTPN6, protein tyrosine phosphatase non-receptor type 6; R848, resiquimod; SHP-1, Src homology 2 domain-containing protein tyrosine phosphatase 1; siPTPN6, PTPN6 small interfering RNA; STING, stimulator of interferon genes; TBK1, TANK-binding kinase 1; TLR7/8, Toll-like receptor 7/8; TME, tumor microenvironment; TNBC, triple-negative breast cancer; TNF-α, tumor necrosis factor-α; αPD-L1, anti-PD-L1 antibody. Composition, Characteristics, and Immune Activation Mechanisms of Triple-Component Nanomedicine Systems Abbreviations: 1-MT, dextro-1-methyl tryptophan; ATP, adenosine triphosphate; Ce6, chlorin e6; cGAMP, 2′3′-cyclic GMP–AMP; cGAS, cyclic GMP–AMP synthase; CpG, CpG oligonucleotide; CPT-11, irinotecan; CQ, 5-carboxy-8-hydroxyquinoline; CRT, calreticulin; diABZI, diamidobenzimidazole STING agonist; GC, gemcitabine monophosphate/prodrug; GEM, gemcitabine; HA, hyaluronic acid; HMGB1, high mobility group box 1; IAHA, aminopropylimidazole- and alendronate-modified hyaluronic acid; IDO, indoleamine 2,3-dioxygenase; IFN-β, interferon-β; IL-6, interleukin-6; IRF3, interferon regulatory factor 3; La3⁺, lanthanum ions; LaP, lanthanum phosphate; MMP-2, matrix metalloproteinase-2; NF-κB, nuclear factor kappa B; NIA, 2-(2-nitroimidazol-1-yl) acetic acid; OX, oxaliplatin prodrug; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PEG, polyethylene glycol; PLA, poly(lactic acid); PTX, paclitaxel; PTPN6, protein tyrosine phosphatase non-receptor type 6; R848, resiquimod; SHP-1, Src homology 2 domain-containing protein tyrosine phosphatase 1; siPTPN6, PTPN6 small interfering RNA; STING, stimulator of interferon genes; TBK1, TANK-binding kinase 1; TLR7/8, Toll-like receptor 7/8; TME, tumor microenvironment; TNBC, triple-negative breast cancer; TNF-α, tumor necrosis factor-α; αPD-L1, anti-PD-L1 antibody. In pancreatic cancer treatment, gemcitabine (GEM), a chemotherapy drug, not only exhibits a short half-life and substantial systemic toxicity but also upregulates PD-L1 expression in tumor cells.183 These limitations collectively restrict its antitumor efficacy. PD-L1 antibodies can effectively counteract GEM-induced PD-L1 upregulation, thereby alleviating tumor-mediated immunosuppressive regulation of T lymphocytes. Furthermore, activation of the stimulator of interferon genes (STING) pathway induces type I interferon secretion and dendritic cell maturation, thereby further enhancing T lymphocyte-mediated antitumor immune responses.184,185 Building upon this foundation, Zheng et al176 engineered a triple-component nanomedicine system (GPS) based on PLA-monoconjugated GEM prodrugs encapsulating the STING agonist diABZI-3 and further surface-modified with a PD-L1 antibody. GEM exerted antitumor effects by directly inducing tumor cell death and promoting tumor antigen exposure. The PD-L1 antibody was designed not only to achieve in situ targeting of pancreatic tumors but also to counteract GEM-induced PD-L1 upregulation. Meanwhile, diABZI promoted DC maturation through activation of the STING-TBK1-IRF3 pathway, thereby enhancing tumor antigen presentation to T lymphocytes. Experimental results demonstrated that, in a Panc02 orthotopic pancreatic tumor mouse model, the GPS group achieved complete tumor clearance by day 35, whereas tumor recurrence occurred in all other treatment groups. In a highly aggressive murine 4T1 triple-negative breast cancer (TNBC) model, the GPS group significantly suppressed primary tumor growth, outperforming both the αPD-L1/GEM NP group and the diABZI NP group.176 In melanoma therapy, activation of DC-mediated adaptive immune responses has emerged as an important therapeutic strategy.186 As professional antigen-presenting cells, DCs are integral to the activation of T cell-mediated adaptive immune responses.156 However, the TME frequently impairs DCs’ maturation and function, thereby inhibiting T cell activation.187 Nonetheless, the traditional cyclic GMP-AMP synthase (cGAS) -STING agonists are hindered by challenges such as limited stability, inefficient intracellular delivery, and vulnerability to nuclease degradation.188 Wang et al177 demonstrated that lanthanum ions (La3⁺) act synergistically with 2′3′-cyclic GMP-AMP(cGAMP) to enhance the STING signaling pathway, thereby improving the efficacy of tumor immunotherapy. Building on this concept, they further developed a “three-in-one” nanomedicine system (IAHA-LaP/siPTPN6 NPs) featuring a core composed of lanthanum phosphate (LaP) co-precipitated with cGAMP and PTPN6 siRNA (siPTPN6).177 Instead of simple physical co-encapsulation, this system delivers three functional components that exert a synergistic effect on STING pathway activation: cGAMP directly initiates STING signaling; La3+ enhances the phosphorylation level of STING to strengthen downstream signal transduction; and siPTPN6 inhibits SHP-1-mediated negative regulation and increases K63-linked ubiquitination of STING. Subsequently, this core was encapsulated within a shell composed of aminopropylimidazole (API)-grafted and alendronate-modified hyaluronic acid (IAHA), which stabilized the core complex and facilitated CD44-mediated tumor-targeted delivery through a pH-responsive release mechanism. La3⁺ significantly augmented the activation of the cGAMP-mediated TBK1/IRF3/NF-κB signaling cascade by enhancing STING phosphorylation. Concurrently, siPTPN6 enhanced STING K63-linked ubiquitination by suppressing SHP-1 expression. In addition, activation of the TBK1/IRF3/NF-κB pathway inhibited lysosomal degradation of STING, thereby producing a three-pronged synergistic enhancement of STING activation and strengthening the immune-stimulatory capacity of dendritic cells. In vivo, IAHA-LaP/siPTPN6 NPs increased the proportion of mature DCs in tumor-draining lymph nodes to 36%, which was 1.4- and 1.2-fold higher than that in the free La3⁺/cGAMP mixture and IAHA-LaP/siNC groups, respectively. In the bilateral B16F10 model, IAHA-LaP/siPTPN6 NPs achieved 1.6- and 1.9-fold higher tumor growth inhibition rates than IAHA-LaP/siNC NPs for primary and distal tumors, respectively (77.7% vs 48.1% and 80.1% vs 42.1%). This enhanced systemic antitumor response was accompanied by at least a 1.3-fold increase in mature DCs in distal tumor-draining lymph nodes relative to all comparator groups (22.8%) and the highest proportion of CD8⁺ T cells in distal tumor-draining lymph nodes (41.5%). Increased splenic central and effector memory T-cell populations further supported the establishment of systemic antitumor immunity and immune memory.189 TNBC presents a formidable challenge in breast cancer management because of its high aggressiveness, early metastatic propensity, and lack of specific therapeutic targets.190,191 The blockade of PD-1/PD-L1 immune checkpoints has emerged as a novel therapeutic strategy for TNBC; however, monotherapy with immune checkpoint inhibitors has demonstrated limited response rates.192 PTX has the potential to induce ICD, thereby enhancing the therapeutic efficacy of PD-L1 blockade.193 Chen et al194 developed a nanomedicine system co-loaded with DEC, PTX, and a PD-L1 antibody (DEC/PTX NPs@αPD-L1). The PD-L1 antibody was conjugated to the nanomedicine surface to facilitate tumor targeting, thereby improving the bioavailability of both DEC and PTX. DEC downregulated the Twist/Snail signaling pathway by inhibiting DNA methyltransferase 1 activity, thereby reversing PTX resistance and tumor metastasis. PTX also acted synergistically with the PD-L1 antibody to inhibit regulatory T cell recruitment and remodel the immune-activated microenvironment. In vitro, DEC/PTX NPs@αPD-L1 induced the highest DC maturation rate (approximately 70%), indicating enhanced immune activation. In the orthotopic 4T1/PTX tumor model, DEC/PTX NPs@αPD-L1 reduced the final tumor volume by approximately 60% relative to the PBS group (approximately 900–1000 vs 2400–2500 mm3). The formulation also decreased the mean number of pulmonary metastatic nodules by approximately 82% (approximately 8 vs 45 nodules), while approximately 60% of the mice remained alive at day 50.194 Discussion In fact, researchers have long recognized that treating tumors with a single drug often fails to produce lasting clinical therapeutic effects, let alone achieving a cure.195 Immunotherapy encounters analogous challenges, which can be attributed to several factors, including the significant risk of drug resistance, the intricate nature of the TME, tumor heterogeneity,196 and plasticity.197,198 For solid tumors in particular, single-agent immunotherapy is further limited by insufficient effector immune cell infiltration, impaired antigen presentation, and the highly immunosuppressive tumor microenvironment, resulting in generally low objective response rates in clinical practice.199,200 As the research progressed, combination therapies are increasingly regarded as crucial for improving the clinical efficacy of tumor immunotherapies.201 Unlike monotherapy, combination therapy involves drugs with differences in polarity, solubility, tissue distribution, and bioavailability.202 These variations may hinder the full realization of synergistic effects between drugs and even lead to potential toxic side effects. In response, researchers have proposed sequential delivery strategies, wherein the two drugs were loaded into two separate nanocarriers (which may be identical or different) and delivered in a specific order.203 This strategy achieved multi-targeted therapy by independently regulating the release timing and action rates of each drug, effectively reducing non-specific toxicity caused by free drug molecules.204 However, this approach of combining multiple nanomedicines still carries certain risks due to differences in the homogeneity and pharmacokinetic characteristics of the various formulations. In contrast, a single nanomedicine delivery system capable of co-loading multiple drugs exhibits uniform physicochemical properties and pharmacokinetic characteristics, thereby better facilitating the synergistic antitumor advantages among different drugs.205 Nevertheless, it should be noted that single-nanocarrier co-delivery systems also face inherent limitations, including loading competition between cargoes, release mismatch caused by disparate diffusion rates, structural instability, and batch-to-batch variability during scale-up production. In this context, a successful multicomponent nanomedicine for immunotherapy requires clear differentiation between simple therapeutic agent co-loading and mechanistically synchronized antitumor immune responses, with core criteria including formally validated synergistic drug ratios, coordinated pharmacokinetic profiles with consistent ratio maintenance during in vivo transport, and spatiotemporally matched immune activation effects. Therefore, co-loading is particularly justified when therapeutically complementary agents exhibit discordant physicochemical or pharmacokinetic properties but require coordinated tumor exposure, defined drug ratios, or sequential immune activation to achieve synergistic effects. In the early stages, research on nanocarriers primarily focused on achieving effective delivery of single drugs.206 With the advancement of nanotechnology, novel nanomedicine delivery systems such as metal-organic frameworks (MOFs), chitosan NPs, and novel nanogels offer the potential for co-delivery of multiple drugs within a single carrier.207–209 Accordingly, formulation requirements should be tailored to the specific characteristics of different immunotherapeutic agents: nucleic acids require protection from degradation and efficient intracellular delivery,210 antibodies and cytokines require preservation of structural and biological activity,13 whereas small-molecule immunomodulators and chemotherapeutic partners often require precise ratio control and coordinated release.14 For solid tumors, these requirements must additionally be integrated with strategies to overcome abnormal vasculature, limited tissue penetration, high interstitial pressure, and the immunosuppressive TME.211 Meanwhile, to load multiple drugs onto the same nanocarrier, researchers have employed various strategies, including physical loading, chemical coupling, and hierarchical loading.212 Among these, physical loading is a direct and commonly employed method. It primarily relies on physical interactions between drug molecules and nanocarriers, including hydrogen bonding, electrostatic interactions, and hydrophobic interactions, etc.213 Physical loading methods can enhance the long-term stability and tolerance to adverse conditions (extreme temperatures, high ionic strength, etc) of bioactive load delivery systems.214 Chemical coupling involves connecting the drug to the nanocarrier via chemical bonds to form a stable complex.215 This method can significantly enhance drug loading capacity and stability, while also enabling controlled drug release through the design of specific chemical bonds.216 Hierarchical loading involves sequentially encapsulating different drugs within distinct layers or regions of the carrier to achieve sequential drug release.22 This facilitates synergistic therapeutic effects while preventing drug-drug interactions. Representatively, the hierarchical co-delivery system of STING agonists and immune checkpoint-targeting siRNA has been verified via formal synergy analysis to achieve true synergistic immune activation, and effectively addresses the release synchronization problem of different nucleic acid cargoes. These strategies demonstrate the distinct characteristics of nanocarriers, providing diverse approaches and technical support for the subsequent design of multicomponent nanomedicine systems. When used in combination therapy, the ratio of different drugs can significantly influence their mechanisms of action and efficacy. Specifically, drug combinations with different ratios may exhibit distinct effects such as synergistic, additive, or antagonistic interactions.217 Maximum synergistic effects can only be achieved when drug combinations enter the TME in optimal proportions.218 Factors such as steric hindrance, polarity and solubility, and electrochemical interactions between different drug molecules and between drug molecules and nanocarriers make the precise control of loading multiple drugs within the same nanomedicine system a formidable challenge.219 In this regard, one approach involves covalently coupling drug combinations using hydrolyzable linkers or similar methods, followed by encapsulating the drug-drug conjugates into NPs for co-delivery. Although this method successfully maintains the loading ratio of two drugs with distinctly different properties, it is limited to a single drug ratio (such as 1:1) and lacks flexibility in regulating drug ratios, resulting in limited clinical applicability.201 Core–shell structured nanosystems with pre-fixed cargo ratios in the inner core represent a promising strategy for maintaining relatively stable cargo ratios during systemic circulation. Therefore, the programmable control of drug ratios within multicomponent nanomedicine systems represents the first critical issue for effectively harnessing the immunotherapeutic antitumor efficacy of combination therapies. Meanwhile, the process of targeting nanomedicine systems to tumors through systemic circulation is complex, facing multiple dynamic interferences such as immune clearance, blood flow, the physical barrier of the endothelial gap, interstitial fluid pressure, and tumor microvasculature. These factors could alter the local concentration ratios of multidrug components, leading to unpredictable therapeutic outcomes.220–222 Therefore, through integrated design of carrier optimization and pharmacokinetics, constructing a co-delivery system with stable in vivo transport represents another critical issue worthy of attention and resolution in subsequent research. The ultimate goal of multicomponent nanomedicine systems is to achieve on-demand drug release at the target site. Therefore, their release dynamics must also be precisely aligned with the drug’s mechanism of action. Ideally, multicomponent drugs should be released programmatically at the target site according to a predetermined sequence and proportion. However, conventional delivery systems often have limited capacity to precisely regulate programmed drug release. The diffusion rates of their internal multicomponent drugs vary significantly and are difficult to control, leading to issues such as the retention of hydrophobic drugs and the sudden release of hydrophilic drugs. This disrupts the pre-set synergistic drug ratios. Currently, several strategies have been developed and applied for precise control of drug release. These included stimulus-responsive carriers that trigger drug release in response to specific signals within the TME (pH, temperature and enzymes, etc),223–225 as well as multistage delivery systems designed to achieve cascading release of multiple drugs at the tumor tissue, intracellular, or subcellular levels through multi-tiered architecture.226,227 Hierarchical and multistage stimuli-responsive delivery systems have shown particular promise in achieving synchronized or programmed release of multiple therapeutic components.228 Although the aforementioned strategies have demonstrated considerable potential in vitro and in preclinical models, their clinical translation still faces multiple bottlenecks. On the one hand, tumor heterogeneity may lead to uncontrollable release of endogenous signals. On the other hand, the complex structures of multilevel delivery systems and similar devices make large-scale production extremely challenging, and batch-to-batch quality consistency for such nanomedicine systems is also difficult to guarantee. Therefore, in subsequent research, overcoming the limitations of single-strategy approaches by leveraging multi-mechanism coordination, multidisciplinary integration, and multidimensional optimization may facilitate a gradual transition in drug release from “passive response” to “active adaptation” within nanomedicine systems. Consequently, achieving on-demand release in multicomponent nanomedicine systems represents the third critical challenge for efficiently realizing the immunotherapeutic antitumor efficacy of synergistic therapies. Acknowledgments This work was supported financially by the National Natural Science Foundation of China (82505042), Natural Science Foundation of Shandong Province (ZR2025QC819); Shandong Provincial Postdoctoral Science Foundation (SDBX2024039). Funding Statement This work was supported by the National Natural Science Foundation of China under Grant 82505042; Natural Science Foundation of Shandong Province under Grant ZR2025QC819; and Shandong Provincial Postdoctoral Science Foundation under Grant SDBX2024039. Data Sharing Statement Data sharing is not applicable to this article as no new data were created or analyzed in this review. Ethics Approval and Informed Consent This article does not contain any studies involving human or animal subjects. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors declare that they have no competing interests. References Associated Data Data Availability Statement Data sharing is not applicable to this article as no new data were created or analyzed in this review.